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The development of small molecules as therapeutic agents for targeted disease treatment
is unable to keep up with the rapid expansion of databases cataloguing disease-causing proteins
enabled by high throughput analysis of patient samples. As an alternative, the use of small
interfering RNA (siRNA) provides a simple means of efficiently and specifically silencing the
expression of these pathogenic proteins without the need for screening and development required
of small molecules. Unfortunately, the delivery of siRNA is not trivial, and existing technology
is characterized by either poor siRNA transfection efficiency or induction of cytotoxicity.
Detailed work by many groups has supported the finding that low transfection efficiency is often
attributable to endosomal entrapment. This phenomenon prevents siRNA from accessing the
cytoplasmic compartment where it is active. Consequently, development of new siRNA vectors
is required to safely promote endosomal escape and delivery of siRNA to the cytoplasm. This
work focuses on the development and characterization of peptides derived from melittin, the
membrane-lytic component of honeybee venom, for siRNA delivery. The most active melittin
derivative, p5RHH, includes modifications to decrease cytotoxicity, increase siRNA binding, and
viii

allow triggered siRNA release in response to the acidic environment encountered during
endocytosis. These peptides bind siRNA to form nanoparticles of 50 to 200 nm in diameter with
a positive zeta potential (+12 mV). This low magnitude surface charge cannot stabilize the
particles against flocculation, necessitating a subsequent coating with serum albumin to achieve
a stable formulation. p5RHH-mediated transfection is characterized by an IC50 in the range of
25 to 100 nM without cytotoxicity at all tested doses. Furthermore, the activity of p5RHH is
attributed to efficient endocytosis via macropinocytosis with nanoparticle disassembly in the
endosome. Particle disassembly releases both siRNA and peptide, allowing p5RHH to disrupt the
endosomal membrane and siRNA to access the cytoplasmic compartment. To demonstrate broad
transfection potential, p5RHH-mediated transfection has been utilized to treat in vitro models of
cancer, angiogenesis, and atherosclerosis. Furthermore, in vivo studies demonstrate the ability of
p5RHH/siRNA nanoparticles to deposit in tumors with little accumulation in clearance organs
such as the liver and spleen. Instead, these studies reveal siRNA clearance via the kidney. Our
results indicate that melittin can be modified for efficient and safe nanoparticle-mediated siRNA
transfection, potentially enabling the clinical use of siRNA. Moreover, our analysis of p5RHH’s
mechanism of action provides a framework to guide the future development of peptide vectors
for siRNA transfection.
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Chapter 1
Introduction
1.1 Nanomedicine
The National Institutes of Health define nanomedicine as “an offshoot of
nanotechnology, [referring] to highly specific medical interventions at the molecular scale for
curing disease or repairing damaged tissues,…”1 This definition highlights the potential of
improved medical treatments by leveraging the unique properties of nanoscale materials. For
example, nanoparticles with diameters less than 1,000 nanometers are expected to provide
improvements over existing medical technology by enhancing the performance of known drugs
and enabling the use of previously bio-incompatible therapeutics.2-6 These highly desirable
characteristics have made nanoparticle development a focus of research since polyacrylamide
nanoparticles were first published in the 1970s.7
Early work in the field of nanoparticle-mediated drug delivery has established that the
ability of nanoparticles to improve drug performance stem from their inherent ability to alter a
drug’s interaction with the body. Notably, nanoparticles improve the pharmacokinetics and
biodistribution of the drugs they carry.8, 9 On the most basic level, nanoparticles enable the use of
potentially beneficial drugs that have been discarded due to a lack of biocompatibility. For
instance, insoluble drugs that are unable to be delivered via oral or parenteral means can be
packaged inside of a carrier nanoparticle for delivery into the body.10
Perhaps of even greater utility is the ability of nanoparticles to enable “targeted delivery,”
a drug delivery paradigm which is characterized by delivery of a therapeutic to a specific
location within the body.11 Examples include delivery of antibiotics to infected tissues,
chemotherapy to tumors, or even anti-inflammatory agents to sites of inflammation.2, 5, 12, 13 By
taking advantage of this property, drugs that have a poor therapeutic index due to systemic side1

effects become clinically relevant because they no longer enter non-target tissues. For instance,
liposomal formulations of the chemotherapeutic, doxorubicin, not only prevent the cardiotoxicity associated with free doxorubicin by decreasing deposition in cardiac tissue but also
improve the ability of doxorubicin to exert anti-tumoral effects.14 This example highlights the
ability of nanoparticles to improve drug delivery to diseased tissue while minimizing the
systemic dose for increased therapeutic benefit. Based on these principles, over 40 nanoparticle
formulations have been approved for clinical use to date, indicating that nanoparticle-based drug
delivery has already begun to impact the practice of medicine.15

1.2 RNA Interference by siRNA
RNA interference (RNAi) refers to an evolutionarily conserved mechanism for posttranscriptional control of protein expression in which short double-stranded RNA (dsRNA)
target specific messenger RNA (mRNA) for degradation, thus preventing protein translation.16
This evolutionarily conserved mechanism is thought to protect against viral infection in yeast
and regulate cellular processes in higher eukaryotes.17 In the context of cellular regulation, the
RNAi machinery is designed to utilize short, 21 to 25 nucleotide, double-stranded micro RNA
(miRNA). miRNA are originally encoded in a long primary RNA which is processed in the
nucleus by Drosha to produce a hairpin-structured primary miRNA (pri-miRNA). pri-miRNA are
then exported from the nucleus for final processing by the RNase III endonuclease DICER
before loading onto the RNA-induced silencing complex (RISC).18 Loaded miRNA subsequently
target the RISC to mRNA through complementary base pairing (Figure 1.1).19, 20 Notably,
mRNA targeting via miRNA only requires partial base pairing by the miRNA sequence. The
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resulting RNAi is traditionally thought to be a result of translational repression, but in some
cases, miRNA can induce mRNA cleavage by the RISC’s argonaute-2 subunit.20, 21
Although RNAi in eukaryotes is natively initiated by the production of endogenous
miRNA, Tuschl et al. have demonstrated that RNAi can be artificially induced by the delivery of
exogenous small interfering RNA (siRNA) into the cytoplasm of mammalian cells.22 siRNA are
short 21 to 23 base pair duplex RNA oligonucleotides with 5’-phosphorylated ends and twonucleotide 3’ overhangs similar to the structure of endogenous miRNA. The “antisense” strand
shares sequence complementarity to a target mRNA, while the “sense” strand serves as a
bystander. When delivered into the cytoplasm of a cell, siRNA can co-opt the native RNAi
machinery and induce assembly of the RISC. The RISC unwinds siRNA, binds the antisense
strand, and cleaves the sense strand.23 This allows the antisense strand to base pair with target

Figure 1.1 RNAi Pathways
Endogenous RNAi is induced by miRNA, which results in translational repression. Alternatively,
exogenous siRNA can induce RNAi by mediating mRNA degradation.
3

mRNA. In contrast to miRNA-based mRNA silencing, siRNA are designed to base pair
completely with the desired mRNA and function solely by inducing mRNA cleavage (Figure
1.1).24 This catalytic mechanism allows one siRNA to induce degradation of multiple mRNAs
and leads to efficient, prolonged downregulation of protein expression for 5 to 7 days. Indeed,
RNAi induced by siRNA is only limited by its dilution through cell division.25
The ability of exogenously delivered siRNA to silence protein expression has limitless
potential for the realization of personalized medicine. By silencing the expression of any
combination of proteins involved in disease pathogenesis on an individual basis, a patient’s
particular disease processes can be specifically inhibited with few off-target toxicities. Notably,
siRNAs can be developed against these targets without the lengthy lead identification and
optimization required of small molecule drug development. Given the advantages of siRNA as a
potential therapeutic, there has been a dramatic push to translate siRNA from a research tool to
clinical applications.26 Recently, clinical trials have been initiated for the use of naked siRNA in
ocular, renal, and hepatic diseases.27
1.2.1 Barriers to the Therapeutic Use of siRNA
There are several significant challenges that need to be resolved before siRNA can be
widely used as a therapeutic. On a cellular level, the mechanism of siRNA action dictates that
siRNA must be delivered to the cytoplasm. This requirement represents the primary hurdle
limiting siRNA’s utility as both a basic science research tool and as a clinical therapeutic.
Unfortunately, siRNA are large (~21 kDa) and highly charged, which hinders its direct
translocation across the hydrophobic core of the cellular membrane.28 Moreover, the barrier
provided by impermeable membrane bilayers not only applies to direct translocation from the
extracellular milieu into the cytoplasm but also cytoplasmic access of siRNA enclosed in
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endocytic vesicles.29 Entrapment of siRNA in endocytic compartments prevents siRNA from
reaching the cytoplasm and accelerates siRNA degradation by the harsh acidic environment
encountered during endosomal/lysosomal trafficking.30
siRNA delivery in an in vivo setting is further complicated by rapid clearance. First, an
abundance of serum RNases causes siRNA cleavage with a half-life of less than 20 minutes.31, 32
Moreover, the size of siRNA (~7.5 nm) allows naked siRNA to be cleared quickly through the
kidney into the urine, as the glomerular basement membrane has a pore size of 10 nm. Detailed
studies have shown that systemically injected siRNA accumulates in the kidney and is excreted
into the urine within one hour.33 The lability of siRNA in serum and rapid clearance of siRNA by
the kidney lead to a short circulation half-life, preventing siRNA accumulation in diseased
tissue.34
Use of siRNA is further limited by the innate immune system. Specifically, pattern
recognition receptors found in both immune and non-immune cells allow highly sensitive
detection of dsRNA, a telltale sign of viral infection.35 These receptors include Toll-like
Receptor (TLR) 3 on the cell surface, TLRs 7 and 8 in the endosomal/lysosomal pathway, and
Protein Kinase R (PKR) and Rig-I in the cytoplasm.36 Spatial separation of these receptors
allows detection of dsRNA in all compartments for a robust antiviral response, leading to
decreased translation of viral proteins and expression of inflammatory cytokines. Fortunately,
detailed studies regarding the activation of these receptors reveal that synthetic dsRNAs less than
23 base pairs with two-nucleotide 3’ overhangs and minimal GA/GU regions are able to
minimize the induction of innate immune responses.35, 37
Despite the myriad barriers preventing the utilization of siRNA as a therapeutic, siRNAbased therapy is moving towards clinical application as solutions to bypass these barriers are
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developed. For example, optimization of siRNA chemistry using phosphorothioate backbones
and 2’O-methyl ribose sugars has improved the resistance of siRNA to serum proteins.38-40 While
these solutions resolve some of the problems associated with siRNA delivery, the most
fundamental difficulties remain unsolved. Without a mechanism to promote siRNA entry into the
cytoplasm, the clinical utility of naked siRNA will be limited.41, 42

1.3 Nanoparticles for siRNA Delivery
The application of nanoparticle technology to siRNA delivery solves many of the
challenges associated with in vivo siRNA delivery. Most importantly, nanoparticles can be used
to package siRNA to improve the pharmacokinetic profile of siRNA. By incorporating siRNA
into a carrier nanoparticle, siRNA are inaccessible to serum endonucleases and thus, protected
from degradation. Moreover, nanoparticles with a diameter larger than 10 nm will exhibit
minimal glomerular filtration and decreased kidney clearance.43 Nanoparticles can also impart
additional benefits on siRNA-based therapy by enabling targeted delivery. Given the potential
for erroneous gene silencing in non-diseased tissue, targeted delivery is critical for increased
patient safety when utilizing siRNA therapies designed to target endogenous genes.44-46 When
considering the challenges associated with systemic delivery of naked siRNA, it appears that the
application of nanoparticle technology is perfectly suited to increase siRNA’s circulation halflife and bioavailability.
On a cellular level, nanoparticles also prove advantageous for increasing siRNA uptake.
By masking the negative charge of the siRNA backbone, nanoparticles can improve association
with the cell membrane via electrostatic association with negatively charged proteoglycans or by
binding cell surface receptors. Both mechanisms can lead to increased endocytosis and cellular
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uptake. With these properties, nanoparticles can be considered to be siRNA-carrying Trojan
horses which protect siRNA and induce cellular uptake while avoiding TLR-mediated activation
of the innate immune system.47
1.3.1 Challenges Facing Nanoparticle-Mediated siRNA Delivery: Design Criteria
Despite the initial success of some nanoparticle-siRNA formulations, widespread use of
nanoparticle-siRNA technology is still hindered by limitations such as stimulation of innate
immunity, vascular constraint, clearance via the reticulo-endothelial system (RES), and
endosomal entrapment.48 When injected into the blood stream, siRNA-carrying nanoparticles
encounter plasma proteins including components of the complement cascade. Complement
activation can cause degradation of liposomal carriers or stimulate a systemic inflammatory
response.9, 49 Intravenous administration of nanoparticles also contributes to poor nanoparticle
biodistribution. Specifically, endothelial tight junctions limit the ability of nanoparticles to
extravasate, thus preventing therapeutics from reaching their target site and promoting clearance
by macrophages in the liver and spleen.50 Even when nanoparticles are able to extravasate and
enter the targeted cell, effective siRNA delivery can be limited by inappropriate subcellular
localization. Nanoparticle entry via endocytosis often constrains nanoparticles to the endosomal
pathway, ultimately resulting in siRNA degradation in the lysosomes.51
These challenges have prevented nanoparticles from achieving the therapeutic benefits
often espoused by the field of nanomedicine. To overcome these barriers, the ideal siRNA
delivery vector should meet the following criteria: 1) package siRNA to prevent degradation by
serum endonucleases and minimize glomerular filtration, 2) provide sufficient circulation halflife to allow delivery to the target organ while avoiding RES uptake, 3) avoid opsonization and
stimulation of an immune response, 4) induce endocytosis via cell surface receptor binding or
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nonspecific electrostatic association with the cell membrane, 5) promote endosomal escape to
deliver siRNA to the cytoplasm, and 6) exhibit minimal cytotoxicity.
As nanoparticles have matured, difficulties associated with toxicity, immune stimulation,
and RES-mediated clearance have been addressed through improved nanomaterials. Notably,
criteria two through four apply to in vivo usage, and while they are not trivial, have been solved
by a combination of pegylation and active targeting.8, 52 Pegylation of nanoparticles decreases the
interaction of serum proteins with nanoparticle surfaces via steric hindrance provided by
hydrophilic polyethylene glycol (PEG) polymers. By preventing opsonization, nanoparticles are
no longer rapidly cleared by scavenger receptor-carrying macrophages in the RES. For instance,
cyclodextrin nanoparticles rely on pegylation to decrease opsonization and therefore limit RES
clearance allowing long circulation half-lives.53, 54 These nanoparticles can then slowly penetrate
tumors to deliver therapeutic siRNA to tumor cells via active targeting to the transferrin receptor.
Unfortunately, existing solutions have had difficulties fulfilling criteria five and six, which are
specific to the siRNA delivery vector itself. Existing siRNA delivery technology has traditionally
exhibited efficient endosomal escape with high cytotoxicity or poor endosomal escape with low
cytotoxicity.55, 56 Consequently, there is a need for new siRNA delivery technology to enable
endosomal escape with minimal cytotoxicity.

1.4 Current siRNA Delivery Technology
1.4.1 Viral Vectors
Early work has utilized adenoviral vectors to deliver plasmids expressing short hairpin
RNA (shRNA), which are converted into siRNA via the nuclease DICER. These methods can
achieve highly efficient plasmid transfection and production of high amounts of encoded
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shRNA.57 However, early clinical trials were halted by excessive inflammatory responses and
induction of cancer due to genomic integration of the delivered plasmid.58-60 These difficulties
suggest that new non-viral siRNA delivery strategies are required to fully realize the promising
therapeutic potential of siRNA.
1.4.2 Cationic Lipids
Cationic lipids are the most efficient and best characterized non-viral vectors for the
delivery of siRNA. The original class of lipid vectors was based on the cationic lipids DOTAP or
DC-Chol mixed with a helper lipid, DOPE, to package siRNA into multi-lamellar lipoplexes.61
Importantly, cationic lipids are also able to induce disruption of endosomal membranes
(endosomolysis) by altering lipid bilayers to favor non-bilayer structures.62 Unfortunately, the
efficiency with which cationic lipids disrupt membrane bilayers also leads to considerable
cytotoxicity.63 A new generation of synthetic lipids (lipidoids) delocalizes cationic charge over a
large headgroup and exhibits both drastically reduced cytotoxicity and increased siRNA
transfection efficiency.64, 65 Unfortunately, in vivo results have not been as successful as those
from in vitro studies owing to heterogeneity in lipid formulations. Nonetheless, existing lipoplex
formulations have reached Phase I clinical trials with moderate success for liver disease.66
However, some similar lipoplex-based therapeutics have been shelved due to stimulation of
systemic immune responses at high doses.67 Although lipoplexes are currently the primary
vectors for in vivo applications, these findings highlight the need for further analysis of lipoplexmediated toxicity.
1.4.3 Cationic Polymers
Cationic polymers offer a high charge density with which to condense and package
siRNA. Traditional polymer vectors include synthetic polymers such as polyethyleneimine (PEI)

9

and cyclodextrin, and natural polymers such as the polysaccharide chitosan.68 These polymers
rely on positively charged groups to neutralize and package siRNA to allow for efficient
endocytosis, while utilizing protonatable moieties to induce osmotic lysis of endosomes via the
“proton sponge effect.”69 This method of endosomolysis relies on buffering of endosomal
acidification by weak bases, allowing the ensuing accumulation of chloride counter-ions to drive
osmotic rupture of the endosome. Despite robust endosomolysis, polymer vectors are difficult to
optimize. The degree of optimization must be carefully controlled, as high degrees of
polymerization provide improved siRNA compaction and transfection but also increase
cytotoxicity via production of reactive oxygen species and destabilization of cellular
membranes.55, 70 Despite these difficulties, polyplexes, notably cyclodextrin-based copolymers,
have entered Phase I clinical trials for targeted cancer therapy. Unfortunately, this trial has failed
to move forward, possibly due to low endosomal escape or nanoparticle disassembly on
glomerular basement membranes in the kidney.71-73

1.5 Cationic Peptides for siRNA Transfection
With the observation that the Trans-Activator of Transcription (TAT) peptide from HIV
can directly translocate across cell membranes to trans-activate the viral promoter in tissue
culture, cell-penetrating peptides (CPPs) have become a widely utilized tool for delivery of
therapeutics.74 Delivery of therapeutics ranging from small molecules to proteins have all been
augmented by CPP technology.75 Based on their hypothesized ability to bypass the cellular
membrane, CPPs were expected to enable cytoplasmic delivery of siRNA while avoiding the
endosomal compartment. Although this has ultimately proven untrue, peptides remain a viable
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option for siRNA delivery due to an ability to promote endocytosis and a relative lack of
cytotoxicity.
1.5.1 Covalent Formulations
Initial attempts to harness peptides for siRNA transfection focused on direct chemical
conjugation to known cell-penetrating peptides such as penetratin and transportan. These studies
reported an IC50 of 25 nM and minimal cytotoxicity.76-78 Unfortunately, these initial studies
were later shown to be confounded by poor purification, as excess unconjugated peptide
augmented the transfection efficiency. Turner et al. demonstrated that after careful purification,
siRNA conjugated to cell-penetrating peptides had minimal transfection capacity, requiring a
concentration of 5 µM to achieve significant knockdown.79-81 They attributed the limited
transfection capacity to endosomal entrapment based on the findings that endosomolytic agents
such as chloroquine were able to release siRNA into the cytoplasm.82 When tested for intratracheal delivery of siRNA to the lung, these purified conjugates did not exhibit any
improvement over naked siRNA alone.83 Additional setbacks included decreased peptide-siRNA
conjugate uptake in the presence of serum proteins.84 Nonetheless, in vitro studies investigating
the use of peptide-oligonucleotide conjugates reinforce the safety of peptide vectors. Only
minimal cytotoxicity has been reported with doses up to 10 µM, indicating a high degree of
safety on a cellular level.85
1.5.2 Non-Covalent Formulations
Due to the limited efficacy of peptide-siRNA conjugates and the finding that excess
peptide imbues improved transfection efficiency, peptide-based siRNA vectors have more
commonly been utilized in non-covalent formulations (Table 1.1). Initial studies examining
siRNA delivery via electrostatic packaging by TAT, penetratin, and transportan all produced
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Table 1.1 Cell-Penetrating Peptides for siRNA Transfection
Peptide
TAT47-57 (YGRKKRRQRRR)

Target Gene
eGFP

IC50
none

Penetratin (RQIKIWFQNRRMKWKK-amide)

Luciferase

none

Transportan (GWTLNSAGYLLGKINLKALAALAKKIL-amide)
TP10 (AGYLLGKINLKALAALAKKIL-amide)

Luciferase
Luciferase

none
none

GFP
VEGF
VEGF

100nM
none
100nM

Luciferase

none

Luciferase
Luciferase, GAPDH,
Cyclin B1
Cyclin B1
Luciferase

>100nM

94

30-50nM

94, 95

1nM
1nM

95

GAPDH

<1nM

97-100

Luciferase
GFP

none
400nM

101

Rn (8<n<15)
R9-RVG
R9
R15
Dermaseptin S4
MPG (Ac-GALFLGFLGAAGSTMGAWSQPKKKRKV-amide)
MPGΔNLS (Ac-GALFLGFLGAAGSTMGAWSQPKSKRKV-amide)
MPG8 (Ac-βAFLGWLGAWGTMGWSPKKKRK-amide)
MPGα (Ac-GALFLAFLAAALSLMGLWSQPKKKRKV-amide)
CADY (GLWRALWRLLRSLWRLLWRA-amide)
dsRBD
TAT-dsRBD

Ref

81, 86
87-89
87
87, 88

90
88, 91
92
93

96

102

minimal siRNA-mediated knockdown despite high levels of siRNA internalization.81, 86, 87
Further treatment with chloroquine increased siRNA-mediated knockdown, revealing that some
of these peptides were unable to achieve sufficient endosomal escape.88 Interestingly, penetratin
and poly-arginine peptides continued to exhibit minimal knockdown in the presence of
chloroquine. This implies that endosomolysis alone is not sufficient for induction of RNAi, but
efficient release from the vector is also required. These initial studies point out the requirement
for peptide vectors to both release siRNA and promote endosomal escape in order to achieve
maximal siRNA transfection efficiency.
Despite these initial difficulties, the development of new peptide sequences has allowed
siRNA delivery with non-covalent formulations. Notably, the transfection efficiency (IC50 less
than 1 nM) of MPG and CADY is much higher than that of covalent strategies (IC50 greater than
5 µM).103-105 Moreover, peptide vectors have demonstrated efficacy in a variety of cell types in
tissue culture as well as successful abatement of cancer progression in mouse models.56
12

Importantly, despite increased peptide content compared to covalent formulations, non-covalent
peptide/siRNA complexes continue to exhibit remarkable safety with minimal toxicity, even at
high µM concentrations. Unfortunately, the limiting factor for non-covalent peptide vectors
appears to be excessive endosomal entrapment as well as decreased transfection in the presence
of serum proteins.98, 106
1.5.3 Non-Covalent Formulations: MPG
Initial success with peptide-mediated siRNA delivery was achieved with MPG, a hybrid
peptide consisting of the fusion sequence from HIV glycoprotein 41 and the nuclear localization
sequence of the SV40 virus. MPG was originally developed for plasmid DNA transfection and
achieves knockdown of target mRNA with an IC50 of 20 to 50 nM.94, 95, 107 Initial work indicated
that MPG-mediated siRNA transfection via direct translocation through the cell membrane.108
However, later studies concluded that MPG/siRNA complexes enter cells via
macropinocytosis.109 Further sequence refinement led to a truncated form, MPG-8, as well as
MPGα, which exhibits increased membrane-inserting properties.95, 96 Both MPG-8 and MPGα
are characterized by sub-nanomolar IC50 when used to target luciferase. However, detailed work
by Veldhoen et al. demonstrated that MPGα is not especially efficient and requires almost two
orders of magnitude more siRNA "per dose" to achieve the same knockdown as Lipofectamine
2000.96 This finding may be attributable in part to endosomal entrapment, as treatment with
chloroquine improved transfection by nearly 20%.
1.5.4 Non-Covalent Formulations: CADY
CADY is the first peptide designed to specifically promote both siRNA binding and
membrane permeability. CADY has an alpha-helical structure with an siRNA-binding face
containing cationic residues and a membrane-binding face enriched in tryptophan residues.99 To
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date, CADY is the most efficient peptide-based siRNA vector with an IC50 less than 0.5 nM.97
Interestingly, CADY appears to function by direct membrane translocation as neither ATP
depletion nor incubation at 4°C inhibits siRNA transfection.100 Nevertheless, CADY may have
limited in vivo applications due to decreased transfection in the presence of serum proteins.98
1.5.5 Non-Covalent Formulations: dsRBD
Dowdy et al. further developed peptide-mediated transfection by utilizing conjugates of
TAT and double-stranded RNA binding domains (dsRBD).101, 102 dsRBD sequences were
modified from Protein Kinase R, a cytoplasmic protein which plays a crucial role in the detection
of viral infection. These TAT-dsRBD conjugates were shown to transfect a variety of difficult to
transfect cell lines such as Jurkat T-cells and endothelial cells in tissue culture with an IC50 near
400 nM and were able to yield significant siRNA knockdown in vivo. Unfortunately, later studies
demonstrated that, due to low binding affinities, a single dsRBD is unable to bind siRNA
efficiently, suggesting that siRNA packaging by TAT-dsRBD is attributable to electrostatic
TAT/siRNA interactions.110

1.6 Melittin as a Basis for Endosomal Escape
It is apparent that peptide-mediated transfection is hampered by poor efficiency due in
part to endosomal entrapment. In this work, we employ melittin derivatives for their membrane
inserting properties as a potential solution to enable endosomal release of siRNA. Melittin is a 26
amino acid alpha helical peptide first purified from the European honeybee in 1958 that has a
high affinity for lipid membranes and ultimately causes membrane lysis in its active form.
Although the exact mechanism of membrane disruption has not fully been clarified, melittin has
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been shown to lyse red blood cells and model membranes.111, 112 Given its lytic nature, melittin
itself has been proposed for the treatment of cancer and bacterial infections.
More recently, melittin has been utilized as an excipient for hepatocyte-targeted siRNA
therapy based on its membrane-lytic properties.113 In these studies, melittin is protected by acid
labile groups that prevent membrane insertion until exposed to the acidic endosomal
environment.114 Activation of melittin in the hepatocyte endosome has proven to be robust and
yields a 500-fold increase in siRNA-mediated protein knockdown in vivo.
Unfortunately, similar studies in which siRNA and melittin are conjugated to a polymer
backbone have not been as successful. These studies have shown that such constructs cause
substantial cytotoxicity in tissue culture and liver necrosis with abdominal bleeding in mice.115117

These conflicting results highlight the difficulties of working with melittin as a therapeutic.

Moreover, melittin has been shown to be less lytic at acidic pH, the same environment found in
endosomes.118 Nonetheless, the apparent ability of melittin to promote endosomolysis implies
that melittin may be a potential solution to the problem of endosomal entrapment.114
Melittin contains a hydrophobic N-terminus and cationic C-terminus similar to the
amphipathic sequence of previously published siRNA-transfecting peptides. In studies of
plasmid DNA delivery, melittin was able to bind DNA but yielded poor condensation due to an
inadequate number of basic residues.119 Polymerization of melittin improved DNA condensation
and yielded moderate transfection. These findings suggest that for stable condensation of siRNA,
additional basic residues must be appended to the native melittin sequence. Furthermore, our lab
has previously demonstrated that N-terminal melittin truncations decrease cytotoxicity by two
orders of magnitude while maintaining the peptide’s propensity to partition into lipid
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membranes.120 By taking advantage of these modifications, melittin derivatives may provide a
starting point for a new class of peptide vectors for siRNA transfection.

Accordingly, we proposed to investigate the following hypotheses:
Chapter 2: Given its amphipathic nature and net positive charge, melittin can be modified to
perform as an siRNA delivery vehicle with minimal cytotoxicity.

Chapter 3: Nanoparticles composed of siRNA and melittin derivatives function by disassembling
in the endosome, releasing free peptide to trigger endosomal escape.

Chapter 4: Melittin derivatives can transfect siRNA into a variety of cell types for the treatment
of clinically relevant disease processes.
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Chapter 2
Novel Melittin-Derived Peptides for siRNA Transfection
2.1 Abstract
Traditional transfection agents such as cationic lipids and polymers have high siRNA
transfection efficiency but cause extensive cytotoxicity. Alternatively, CPP-based transfection
agents exhibit improved cytotoxicity profiles but do not have the efficiency of existing lipidic
agents due to endosomal entrapment. As a consequence, we propose an alternative strategy for
efficient peptide-mediated siRNA transfection by starting with melittin, a known membrane-lytic
peptide. Through the incorporation of modifications designed to decrease cytotoxicity and
improve siRNA binding, we have generated a panel of melittin derivatives with the ability to
transfect siRNA. The most active variant, p5RHH, can complex siRNA to form nanoparticles 50
to 200 nm in diameter at peptide to siRNA ratios of 100 to 1. These nanoparticles are stabilized
by weak electrostatic repulsion (zeta potential +12 mV) with loss of activity over time due to
flocculation. Despite particle instability, p5RHH does not induce cytotoxicity and exhibits high
efficiency with greater than 50% GFP knockdown at 50 nM, as determined by RT-PCR.
Moreover, kinetically stabilized formulations can be achieved by coating the particles with
albumin, preventing flocculation for over 72 hours. These data confirm that our strategy for
development of siRNA-transfecting peptides can provide an alternative avenue to safe and
effective siRNA transfection.

NOTE: Portions of this chapter are adapted from previously published work.
Hou, K.K.; Pan, H.; Lanza, G.M.; Wickline, S.A., Melittin derived peptides for nanoparticle
based siRNA transfection. Biomaterials 2013, 34 (12), 3110-3119.
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2.2 Introduction
RNAi induced by siRNA has been proposed as a highly effective therapy for myriad
diseases including cancer and atherosclerosis.1, 2 However, despite nearly two decades of intense
research since ground breaking work by Tuschl et al. revealed the potential for siRNA in
mammalian cells, siRNA therapeutics have demonstrated limited success in translation to clinical
applications.3, 4 The major barriers preventing successful siRNA-based therapeutics comprise
poor cellular uptake and instability of free siRNA in serum. Its large molecular weight (~21 kDa)
and high charge density prevent siRNA from passing through the cellular membrane to reach the
cytoplasmic compartment where siRNA is active, thus blocking successful induction of RNAi.
These traits, combined with a serum half-life of less than 20 minutes, necessitate the packaging
of siRNA by transfection agents.5 Such agents can protect siRNA from serum endonucleases and
promote siRNA uptake through endocytosis. Unfortunately, endocytic pathways present a second
barrier, as siRNA must escape the endosomal/lysosomal compartment where it is degraded by an
increasingly acidic environment.5-9
Despite these challenges, cationic lipids and polymers have been successfully employed
for siRNA transfection.2, 5, 6, 10-12 Unfortunately, these classes of transfection agents often exhibit
unacceptable cytotoxicity.13-16 The incorporation of cationic lipids into membrane bilayers within
cells promotes siRNA release into the cytoplasm but also causes generation of reactive oxygen
species and Ca+2 leakage, a side effect shared by high molecular weight polyetheyleneimine
cationic polymers.15-17 Despite continued development of these siRNA vectors with the goal of
reducing cytotoxicity, these agents have experienced difficulties when administered in vivo due
to aggregation with serum proteins and complement activation.18-20 If the problem of systemic
siRNA delivery is to be solved, new classes of siRNA transfection agents need to be developed.
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CPP-based siRNA transfection agents have shown promise with respect to reducing
cytotoxicity.21-25 Although CPP-based siRNA transfection appears nearly free of cytotoxicity,
peptide-based transfection agents have not achieved the high efficiency of traditional lipidic
transfection agents. Some insight has been provided by the studies of Veldhoen et al., which
suggest that peptide-based transfection is limited by lysosomal trapping.26 Despite early work
showing that CPPs mediate siRNA uptake in an energy independent manner,27, 28 it appears that
nanoparticles produced by the assembly of CPP and siRNA enter cells via endocytosis and must
escape the endosomal/lysosomal pathway to gain access to the cytosolic compartment.21, 22, 29, 30
With this barrier in mind, existing CPP technology has achieved a new level of sophistication
through the chemical conjugation of CPPs to membrane-active lipids or endosomolytic agents.24,
31-33

Despite these advances, achieving transfection efficiency comparable to that of lipids has

remained elusive.
2.2.1 Modified Peptides for siRNA Transfection
Modifications to cell-penetrating peptides for increased endosomal escape have centered
on three modifications: fusion to pH-sensitive fusogenic viral peptides, conjugation to lipidic
moieties, and modification with buffering agents to promote osmotic rupture of endosomes
(Table 2.1).8, 34 Standard CPPs such as penetratin and TAT have been fused with portions of
influenza proteins hemagluttin-2 (HA2), LK15, or N-E5L which mediate viral escape from the
endosome when exposed to acidic pH.35-38 This functional pH-triggered structural change
increases the alpha helical content of the peptide and promotes insertion into the endosomal
membrane. In vitro, HA2 fusions have shown the ability to improve siRNA transfection when
packaged by CPP.35 Unfortunately, this modification increases the cytotoxicity of the peptide
with significant cell death at 1 µM.35 Furthermore, these fusion peptides are not maximally
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efficient as treatment with chloroquine improves siRNA transfection. This indicates that
endosomal entrapment is a problem that is not completely addressed by these methods.36
Additional attempts to increase the membrane-disruptive potential of cell-penetrating
peptides come in the form of conjugation to lipids, most commonly stearyl moieties.33, 39
Originally developed for plasmid DNA, stearylated peptides also improve the transfection of
small oligonucleotides such as siRNA and splice-correcting oligonucleotides.40, 41 For these
purposes, stearyl-TP10 has proven to be more effective than stearyl-penetratin, stearyl-TAT, or
stearyl-R8. Studies utilizing un-stearylated peptides suggest that differences in these stearylated
variants may be due to the ability of the peptide to release siRNA.42, 43 Moreover, in the case of
stearyl-TP10, authors noted that improved transfection may not be due to improved endosomal
escape but may actually be attributable to improved particle stability and increased siRNA
uptake.42 In fact, treatment with chloroquine doubled siRNA-mediated knockdown, again
revealing poor endosomal release.
The importance of endosomal pH buffering as a release mechanism has led researchers to
take advantage of histidine residues as a potential trigger for endosomal escape.44 Histidine
residues are unique for their ability to be protonated at acidic pH (pKa ~6) while remaining
uncharged at neutral pH. By incorporating high percentages of protonatable histidine residues,
poly-arginine and TAT have been modified to increase their ability to deliver nucleotides to the
cytoplasm. For instance, the addition of ten histidine residues to TAT improves plasmid DNA
transfection by 7000 fold over TAT itself.45
Other researchers have combined these strategies to improve peptide-mediated
endosomal escape. By taking advantage of stearylation and conjugation to the proton-buffering
agent chloroquine, Andaloussi et al. have created Pepfect6, which has an IC50 less than 10 nM
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in a variety of cell types.46-48 Despite high efficiency transfection of hepatocytes in vivo, further
analysis reveals that Pepfect6/siRNA particles demonstrate an increase in size and a mild
decrease in transfection in the presence of serum proteins.46 Despite these difficulties, the
incorporation of these modifications is indicative of the need for supplementary endosomolytic
agents to improve the endosomal-escape properties of existing CPPs.
In this chapter, we propose an alternative strategy for efficient peptide-based siRNA
transfection based on modification of the cytolytic peptide, melittin, which is the pore forming
component of honeybee venom. Melittin’s ability to form pores in membrane bilayers suggests
that it can serve as a foundation for the development of simple peptides, which can improve

Table 2.1 Modified Peptide Vectors
Modified Peptides
TAT
Stearylation
HA2 conjugation
LK15 conjugation
Histidine10 conjugation

Benefit

Ref

Improved siRNA uptake/Endosomal escape
pH-triggered endosomal escape
Endosomal escape
pH-triggered endosomal escape

40

Penetratin
HA2 conjugation
Stearylation

pH-triggered endosomal escape
pH-triggered endosomal escape

51

Poly-Arginine
Stearylation
Myristoylation
Cholesterol conjugation
Stearylation and insertion of histidine

Endosomal escape
Brain targeted delivery
Increased particle stability/Endosomal escape
Endosomal escape

Poly-Lysine
Insertion of histidine

Endosomal escape

TP10
EB1
Stearylation
Stearylation and chloroquine conjugation

Endosomal Escape
Improved siRNA uptake/Endosomal escape
pH-triggered endosomal escape

MPG8
Cholesterol conjugation

Improved particle stability/Endosomal Escape

60

Calcitonin-derived peptides
Myristoylation
HA2 conjugation

Improved siRNA uptake/Endosomal Escape
Improved siRNA uptake/pH-triggered endosomal escape
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30

49
50
45

42

42, 52
53
54
55

44, 56, 57

58
42
46, 48, 59

36

endosomal escape, thereby setting the stage for efficient siRNA-mediated RNAi. Previous work
in our lab has shown that melittin can be modified to attenuate its cytotoxicity while maintaining
its propensity for interacting with membrane bilayers.61, 62 By incorporating these changes along
with modifications to enhance peptide/siRNA interactions, we hypothesize that melittin-derived
peptides can safely transfect siRNA by improving siRNA delivery to the cytoplasmic
compartment.

2.3 Materials and Methods
2.3.1 Preparation of Peptide/siRNA Nanoassemblies and Analysis
Melittin derivatives were synthesized by Genscript (Piscataway, NJ), dissolved at 10 mM
in RNase/DNase free water (Sigma, St. Louis, MO) and stored in 4 µL aliquots at -80˚C before
use. p5RHH/siRNA transfection complexes were prepared by diluting p5RHH 1 to 200 in
phosphate buffered saline (PBS, Sigma), vortexing for 30 seconds followed by addition of the
appropriate amount of siRNA (stock concentration of 10 µM in 1x siRNA buffer (Thermo
Scientific, Waltham, MA)) and incubating for 40 minutes at 37˚C with shaking on an Eppendorf
Thermomixer R. Resulting nanoparticles were analyzed for siRNA incorporation by resolution
on a 12% polyacrylamide gel followed by ethidium bromide staining. Dynamic light scattering
(DLS) and zeta potential measurements were performed on a Zeta Plus particle sizer
(Brookhaven Instruments, Newton, MA). Serum stability analysis was performed by incubating
freshly formed peptide/siRNA nanoparticles in 500 µg/mL human serum albumin (HSA, Sigma)
overnight followed by DLS and zeta potential measurements. Wet-mode atomic force
microscopy was performed by ARC Technologies (White Bear Lake, MN).
2.3.2 Analysis of p5RHH Disulfide Bond Formation
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p5RHH was diluted to 5 mM in 20% DMSO and allowed to oxidize for 24 to 72 hours at
4°C. Disulfide bond formation was quantified using Ellman’s Reagent (ER) (20 mM stock in
buffer 8 (0.1 M NaH2PO4, 0.2 mM EDTA, pH 8)). Briefly, p5RHH was diluted 1 to 500 into ER
working solution (40 µM) and allowed to incubate at 37°C for 25 minutes. After the incubation,
UV absorbance was measured at 412 nm. A standard curve of freshly prepared L-cysteine was
used to allow quantification of thiol oxidation.
2.3.3 Cell Culture
B16-F10 (ATCC, Manassas, VA) cell lines were maintained under standard cell culture
conditions (37˚C and 5% CO2 in a humidified incubator) in DMEM (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Gibco). B16-F10 cells stably expressing GFP were
produced as follows: B16-F10 were transfected (Lipofectamine 2000, Invitrogen) with a fusion
of eGFP (pEGFP-N1, Clontech) and the PEST sequence from mouse ornithine decarboxylase
(S421-V461) in pEF6V5HisTOPO (Invitrogen); cells were selected for four rounds with cell
sorting by flow cytometry without antibiotic selection; an aliquot of cells was maintained in
continuous culture for a month without a noticeable change in eGFP expression.
2.3.4 siRNA Transfection
Cells were plated in 6-well plates 12 hours before transfection and cultured under
standard cell culture conditions. p5RHH/siRNA nanoparticles were prepared and incubated with
cells for 4 hours in a final volume of 1 mL Optimem I (Gibco) or appropriate media
supplemented with 10% FBS. Transfections were scaled accordingly for cells plated in 12-well
plates based on cell culture surface area. After transfection, cells were washed twice with PBS
and incubated with standard cell culture medium for another 24 to 72 hours before analysis.
Lipofectamine 2000 was used in accordance with the manufacturer’s protocol. Briefly,
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Lipofectamine 2000 was diluted in Optimem I to a final concentration of 8.4 µg/mL and
incubated at room temperature for 15 minutes. siRNA was then added to the diluted lipid and
incubated for another 40 minutes before dilution to 1 mL total volume with Optimem I for
transfection. eGFP siRNA (Sense: 5’-GACGUAAACGGCCACAAGUUC-3’) was purchased
from Sigma. Scrambled siRNA was purchased from Qiagen (Valencia, CA).
2.3.5 Plasmid DNA Transfection
HEK293 cells were plated in 6-well plates at a density of 150,000 cells/well. 3 µg of
plasmid DNA coding for GFP was mixed with p5RHH at a charge ratio of 12 to 1 for 40 minutes
at 37°C. Cells were transfected overnight, and GFP expression was observed via fluorescence
microscopy. Lipofectamine 2000 was used in accordance with manufacturer recommendations.
2.3.6 Western Blotting
24 or 48 hours after transfection, 100 to 200 µL RIPA buffer (10 mM Tris–HCl (pH 7.5),
150 mM NaCl, 1.0% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
1 mM EDTA, 5% glycerol) with 1 mM PMSF and Complete Protease Inhibitor Cocktail (Roche)
was added to each well of a 6-well plate and incubated on ice for 1 hour. Cell lysates were then
centrifuged at 4˚C for 5 minutes and supernatants stored at -20˚C. Lysates were resolved on
Nupage Bis-Tris gels (Life Technologies) and transferred to 0.22 µm nitrocellulose before
blocking in 5% bovine serum albumin (Sigma) in TBS-T. Primary antibodies used included
rabbit anti-GFP (1:1,000, Novus Biologicals, Littleton, CO) and mouse anti-β-actin (1:1,000,
Sigma), Secondary antibodies used included anti-rabbit HRP (1:5,000, Santa Cruz
Biotechnology) and anti-mouse HRP (1:5,000, Santa Cruz Biotechnology). Blots were developed
using ECL Western Blotting Substrate (Pierce, Rockford, IL).
2.3.7 Real-Time PCR
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24 hours post-transfection, cDNA was produced using the FastLane Cell cDNA kit
(Qiagen). cDNA was stored at -20˚C until use. mRNA levels were quantified on an Applied
Biosystems 7300 System (Applied Biosystems, Carlsbad, CA) using iTaq SYBR green with
ROX (Bio-Rad, Hercules, CA). Quantitect Primer Assay (Qiagen) provided gene-specific
primers for each gene. Genes of interest were normalized to species-appropriate β-actin. Results
are reported as the average “fold change” relative to untreated controls for three separate
experiments.
2.3.8 Flow Cytometry
24 hours after B16-GFP cells were transfected with p5RHH/siRNA nanoparticles
containing GFP-specific or scrambled siRNA, cells were trypsinized and resuspended in FACS
buffer (HBSS with 0.2% FBS and 0.5 mM EDTA) for analysis of GFP fluorescence.
2.3.9 Cell Viability Assay
Cell viability was determined 72 hours post-transfection using Alamar Blue (Life
Technologies). Briefly, Alamar Blue was diluted 1 to 10 into phenol red-free media and
incubated with cells for 2 to 4 hours. Fluorescence was measured on a fluorescent plate reader
with excitation at 570 nm and emission at 585 nm (Varian Cary Eclipse, Agilent Technologies,
Santa Clara, CA).

2.4 Results
2.4.1 Screening for siRNA Knockdown
Knockdown of GFP in B16 cells stably expressing GFP-PEST allowed quick screening
for effective siRNA knockdown of GFP expression as the addition of the PEST sequence leads
to ubiquitination and shortens GFP half-life from 26 to 10 hours.63 Melittin derivatives were
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chosen based on modifications designed to decrease cytotoxicity as well as improve interactions
with oligonucleotides. These peptides were screened for their ability to deliver GFP siRNA to
initiate GFP knockdown in B16-GFP cells (Table 2.2). Three peptide/siRNA ratios
corresponding to charge ratios of 6 to 1, 12 to 1, and 24 to 1 were chosen to allow sufficient
positive charge to neutralize and condense siRNA. While melittin itself was too toxic in this
concentration range, four melittin derivatives exhibited GFP knockdown as demonstrated in
Figure 2.1. A quick comparison of the peptide sequences exhibiting knockdown reveals that all
functional sequences contain histidine residues, pointing to a potential role for these residues in
siRNA transfection by melittin derivatives. Of these four, p5RHH and p5RWRH exhibited the
best performance. Ultimately, p5RHH was chosen for further characterization and optimization
of formulation based on its ability to transfect siRNA when formulated in multiple buffers
including phosphate buffered saline (PBS), Hank’s Balanced Salt Solution (HBSS) and Optimem
I (unpublished observations).
2.4.2 Optimization of Nanoparticle Formulation
Based on the overall net positive charge of the melittin derivative, p5RHH, we
anticipated that p5RHH would interact electrostatically with negatively charged siRNA.
Therefore, formulation of p5RHH/siRNA nanoparticles was optimized based on p5RHH to
siRNA ratio as well as the incubation duration allowed for nanoparticle formation. We monitored
these interactions at varying peptide to siRNA ratios by gel retardation assays, in which only
unbound siRNA could migrate into the polyacrylamide gel under the presence of an electric
field. In these assays, a set amount of siRNA was mixed with increasing amounts of p5RHH in
PBS for 40 minutes before loading on a gel (Figure 2.2a). From these gels, it is apparent that a
peptide to siRNA ratio of at least 50 to 1 is required to stably compact siRNA.
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Table 2.2 Sequences Screened for siRNA Transfection
Sequence

Modification

Hypothesis

Melittin
GIGAVLKVLTTGLPALISWIKRKRQQ

--

--

Peptide 5C
VLTTGLPALISWIKRKRQQC

N -Terminal
Truncation

Increased Safety

Peptide 5RWR
VLTTGLPALISWIKRKRQQRWRRRR

N-Terminal
Truncation
C-Terminal Arg

Increased siRNA
compaction

Peptide 5RWRH
VLTTGLPALISWIKRKRQHRWRRRR

N-Terminal
Truncation
C-Terminal Arg, His

Increased siRNA
compaction with
pH-triggered
release

Peptide 5RH
VLTTGLPALISWIRRRHRRC

N-Terminal
Truncation
C-Terminal Arg, His

Peptide 5RHH
VLTTGLPALISWIRRRHRRHC

Particle
composition
(peptide:siRNA)
62:1
124:1
248:1

Charge ratio Able to
(+/-)
transfect?
6:1
12:1
24:1

No
Toxic
Toxic

62:1
124:1
248:1

6:1
12:1
24:1

No
No

28:1
56:1
112:1

6:1
12:1
24:1

No
No
-

28:1
56:1

6:1
12:1

Yes
No

112:1

24:1

No

pH-triggered
release

50:1
100:1
200:1

6:1
12:1
24:1

No
Yes
No

N-Terminal
Truncation
C-Terminal Arg, His

pH-triggered
release

50:1
100:1
200:1

6:1
12:1
24:1

Yes
Yes
Yes

Peptide 5RH-AA
VAKVLTTGAPALISWIRRRHRRC

N-Terminal
Truncation
Leu to Ala mutation

Increased
endosomal
disruption

50:1
100:1
200:1

6:1
12:1
24:1

No
No
No

Peptide 5RH-LL
VLKVLTTLAPALISWIRRRHRRC

N-Terminal
Truncation

Increased
endosomal
disruption and pore
formation

50:1
100:1

6:1
12:1

No
Yes

200:1

24:1

No

Figure 2.1 Screening of Melittin Derivatives
Four melittin derivatives generate GFP knockdown: (a) p5RWRH, (b) p5RH, (c) p5RHH, and (d) p5RHLL. (–) B16-GFP control, (–) GFP siRNA-treated cells, (–) Fraction exhibiting knockdown.
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This finding is corroborated by flow cytometry data, which show a lack of GFP
knockdown at p5RHH to siRNA ratios below 50 to 1 (Figure 2.2b). Indeed, transfection
efficiency improved with increasing p5RHH content until maximal GFP knockdown at a p5RHH
to siRNA ratio of 150 to 1. In contrast, scrambled siRNA had no effect on GFP expression levels
under the same conditions (unpublished observations). Importantly, Alamar Blue assays revealed
that p5RHH/siRNA nanoparticles of varying peptide to siRNA composition did not exhibit any
cytotoxicity when delivering siRNA at 50 nM (Figure 2.2c). Although there was no sign of
cytotoxicity associated with the peptide at ratios up to 200 to 1, we sought to minimize exposure
to p5RHH and selected a p5RHH to siRNA ratio of 100 to 1 for the remaining experiments.
The interaction of p5RHH with siRNA to form particles is expected to evolve kinetically
with increased siRNA incorporation and particle formation over time. To determine the optimal
incubation duration to allow p5RHH/siRNA nanoparticle formation, p5RHH and siRNA were
mixed in PBS and aliquots were taken out for transfection every ten minutes. Comparison of the
transfection efficiency provided by each aliquot demonstrates that peak transfection efficiency
occurred after incubation for 40 minutes with diminishing transfection thereafter (Figure 2.3a).
2.4.3 Nanoparticle Characterization
Nanoparticles formed at various peptide to siRNA ratios were then examined by dynamic
light scattering and zeta potential analysis after 40-minute incubations. These data revealed that
particle size is tied closely to the effective surface charge (Table 2.3). Particles carrying a surface
charge near 0 mV exhibited the largest diameter, while particles with a zeta potential of greater
magnitude had smaller diameters. The smallest particle size of 190 nm was found to be produced
with a peptide to siRNA molar ratio of 100 to 1 or a charge ratio around 12 to 1 (+/-). It is
important to note that increasing p5RHH to siRNA ratio to 200 to 1 (doubling the +/- ratio to
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Figure 2.2 Optimization of Peptide to siRNA Ratio
(a) Gel retardation assay shows that a p5RHH to siRNA ratio of 50 to 1 is required to stably complex
siRNA. (b) FACS analysis of GFP knockdown by p5RHH/siRNA formulations of varying peptide to
siRNA ratios show increasing knockdown at ratios from 50 to 1 to 150 to 1. (c) Cell viability assays
confirm a lack of cytotoxicity for all peptide to siRNA ratios when transfecting 50 nM siRNA.

Table 2.3 Nanoparticle Characterization
Particle Composition Charge Ratio Particle Size Polydispersity
(peptide/siRNA)
(+/-)
(nm)
Index

Zeta
Potential
(mV)

10:1

1.2:1

300

0.110

-13±1.6

25:1

3:1

830

0.350

-2.3±3.2

50:1

6:1

600

0.220

3.7±0.5

100:1

12:1

190

0.120

12.0±0.7

200:1

24:1

320

0.110

13.1±0.7
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24 to 1) does not change the zeta potential but results in an increased particle size. This
phenomenon has been previously reported with other peptide transfection agents, although the
cause has not yet been established.64
It is important to point out that the particle size reported by DLS is the intensity-weighted
average, and this number is calculated assuming a monomodal nanoparticle distribution. In
reality, dynamic light scattering reveals that the 40-minute formulation actually contains a
bimodal distribution with populations at ~100 nm and ~500 nm (Figure 2.3b). After an additional
40 minutes, a shift in the particle populations occurs - with a decrease in particles around 100 nm
and an increase in particles at 500 nm. Additionally, a new population at larger than 2 µm is also
recorded (Figure 2.3c). By two hours, the majority of the particles are 500 nm and larger (Figure
2.3d). The increase in particle size over time implies that the particles’ zeta potential is not high
enough to stabilize them against further aggregation.
Deep-etch electron microscopy confirms the multiple populations revealed by DLS.
Specifically, electron microscopy shows particles ~20 nm in diameter (Figure 2.4a), ~100 nm in
diameter (Figure 2.4b), as well as large aggregates (Figure 2.4c). Based on these images, the
aggregation process is quite clear - the ~100 nm clusters appear to be comprised of smaller ~20
nm particles, and the large aggregates appear to be flocs of ~100 nm clusters. Although these
populations are different than those calculated by DLS, it is possible that the ~20 nm
nanoparticles are not captured by DLS due to their low light scattering secondary to their small
size. Nevertheless, it appears as though formulations consisting of only peptide and siRNA are
not kinetically stable, and this instability may contribute to the decrease in transfection efficiency
with increased incubation duration.
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Figure 2.3 Temporal Evolution of p5RHH/siRNA Nanoparticles
(a) Following transfection efficiency over time shows particle formation over 40 minutes with a slow
decrease in transfection activity over time. (b) Number-weighted plot of particle diameter shows
populations at 100 nm and 500 nm at 40 minutes. (c) By 80 minutes, a larger population at 5 µm appears.
(d) At 120 minutes, 100 nm diameter particles are no longer visible.

Figure 2.4 Deep-Etch Electron Microscopy of p5RHH/siRNA Nanoparticles
p5RHH/siRNA formulations contain particles ~20 nm in diameter (a), clusters of particles ~100 nm in
diameter (b), and large flocs (c).
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Figure 2.5 Peptide Dimerization Alters Transfection Efficiency
(a) Peptide dimerization induced by disulfide bond formation improves p5RH knockdown of GFP. (b)
Peptide dimerization decreases p5RHH transfection efficiency.
	
  

2.4.4 p5RHH Dimerization Decreases Transfection Efficiency
Similar to many peptide vectors, p5RHH contains a C-terminal thiol in the form of a
cysteine residue.27 The ability for these thiol groups to disulfide bond leading to dimer formation
has been shown to improve the delivery of plasmid DNA due to improved DNA condensation.65
Dimerization of p5RHH and p5RH was induced by incubation of free peptide in 20% DMSO for
24 to 72 hours. Free thiols were then quantified by colorimetric assays using Ellman’s Reagent.
Comparison with a standard curve of freshly dissolved L-cysteine revealed that peptides
removed from storage at -80°C were monomeric, whereas DMSO was able to drive peptide
dimerization. By 24 hours, 45% of the thiols were dimerized, and by 72 hours, all of the peptide
had dimerized. When we compared these peptides against monomeric peptide we found p5RHH
activity to diminish with increased dimerization (Figure 2.5b), but p5RH activity increased
(Figure 2.5a). While it appears that the utility of peptide dimerization is dependent on the peptide
itself, it is clear that the activity of p5RHH does not depend on peptide dimerization.
2.4.5 Comparison with Lipofectamine 2000
Dose-response analysis by flow cytometry revealed that GFP knockdown mediated by
p5RHH is efficient with an ability to decrease GFP expression in ~70% of cells at concentrations
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as low as 10 nM (Figure 2.6a). However, these FACS analyses reveal that p5RHH falls short of
Lipofectamine 2000 at high concentration (200 nM) and low concentration (10 nM) (Figure 2.6),
hinting at an as yet undetermined source of inefficiency. Additional western blotting (Figure
2.7a,c) demonstrates that scrambled siRNA has no effect on GFP expression, while RT-PCR
confirms that p5RHH is less efficient than Lipofectamine 2000 (Figure 2.7b,d). Specifically,
p5RHH has an IC50 of 50 nM for GFP knockdown in B16-GFP cells compared to an IC50 of 10
nM for Lipofectamine 2000. However, it is readily apparent that p5RHH exhibits a dramatically
reduced cytotoxicity profile compared to Lipofectamine 2000. This melittin derivative causes
only a minor (~3%) decrease in cell viability, even at the highest tested concentrations (Figure
2.7c,f).
2.4.6 p5RHH Performance in the Presence of Serum
To ensure that our particles are stable in the presence of serum proteins, we incubated
p5RHH/siRNA nanoparticles in 500 µg/mL human serum albumin (HSA) for 30 minutes or
overnight. When we tested the activity of these particles, their ability to knockdown GFP
expression was the same as fresh nanoparticles (Figure 2.8a). In comparison, nanoparticles
incubated without HSA had no transfection ability after incubating for 12 hours. Confocal
microscopy confirmed the ability of p5RHH to deliver oligonucleotides to the cytoplasm in the
presence of serum proteins (Figure 2.8c,d). These data suggest that serum proteins do not
decrease transfection by p5RHH and reveal that HSA may in fact be beneficial for particle
stability.
Detailed characterization of albumin’s effect on particle stability was performed using
dynamic light scattering, wet mode atomic force microscopy, and zeta potential analysis. DLS
revealed that the average size of nanoparticles incubated with HSA increased marginally from
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Figure 2.6 FACS Comparison of p5RHH and Lipofectamine 2000
Comparison of GFP knockdown by p5RHH and Lipofectamine 2000 at 10 nM (a), 50 nM (b), and 200
nM (c) reveals that p5RHH is less effective at low and high concentrations.

Figure 2.7 Comparison of p5RHH and Lipofectamine 2000 GFP Knockdown and Cytotoxicity
p5RHH mediates sequence-specific knockdown of GFP with an IC50 of 50 nM as determined by western
blotting (a) and RT-PCR (b) without cytotoxicity (c). Lipofectamine has an IC50 of less than 10 nM as
determined by western blotting (d) and RT-PCR (e) but exhibits cytotoxicity at all concentrations (f).
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Figure 2.8 Albumin Stabilizes p5RHH/siRNA Nanoparticles
(a) p5RHH/siRNA nanoparticles incubated in 500 µg/mL human serum albumin maintain transfection
efficiency overnight. (b) Wet-mode AFM reveals stabilization of p5RHH/siRNA nanoparticles with a
mean diameter of 55 ± 18 nm. (c) Confocal microscopy 24 hours post-transfection confirms Cy3-labeled
oligonucleotide (final concentration 100 nM) transfection in Optimem I. (d) Transfection in full media
containing 10% fetal bovine serum does not affect delivery of Cy3-labeled oligos. (Scale bar = 10 µm)

Table 2.4 Characterization of Albumin-Coated Nanoparticles
Particle Size Polydispersity
(nm)
Index

Zeta Potential
(mV)

p5RHH/siRNA -HSA
(30 minutes)

190

0.120

12.0±0.7

p5RHH/siRNA -HSA
(12hours)

>5,000

--

--

p5RHH/siRNA +HSA
(30 minutes)

190

0.194

-7.0±1.0

p5RHH/siRNA +HSA
(12 hours)

220

0.191

-5.5±1.5
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190 nm to 220 nm when compared with freshly prepared particles but remained stable for up to
12 hours. On the other hand, plain p5RHH/siRNA nanoparticles exhibited severe aggregation
(Table 2.4). Given the difficulty of understanding heterogeneous nanoparticle populations with
DLS, we also utilized wet mode AFM, which confirmed that the majority of nanoparticles have a
size of 55 ± 18nm despite the presence of some larger aggregates (Figure 2.8b). These findings
confirm a lack of continued aggregation upon addition of serum albumin.
To determine if albumin might be coating the nanoparticles’ surface, zeta potentials were
measured. These studies reveal that the surface charge of nanoparticles incubated in the presence
of albumin switched from a 12 mV to -7 mV, suggesting that nanoparticles were coated with
negatively charged albumin (Table 2.4). When considered alongside our analysis of particle
stability, these experiments indicate that coating the particles with albumin stabilizes them
against continued aggregation without adverse effects on transfection efficiency.
2.4.7 Transfection of Plasmid DNA
Given p5RHH’s ability to package and transfect siRNA, we also examined its ability to
transfect plasmid DNA. We transfected HEK293 cells with 3 µg of DNA in a 6-well plate. 24
hours post-transfection, cells were monitored for GFP expression. p5RHH was not as efficient as
Lipofectamine 2000 with only 1 to 2% of cells exhibiting GFP expression. The increased
transfection provided by Lipofectamine 2000 is evident by fluorescence microscopy (Figure
2.9a,b).

2.5 Discussion
Our lab has previously explored highly efficient siRNA delivery methods based on
cationic lipids in a novel perfluorocarbon nanoemulsion formulation.66 Despite the high
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Figure 2.9 p5RHH Mediates Plasmid DNA Transfection into HEK293 Cells
(a) Transfection of a GFP-containing plasmid by Lipofectamine 2000. (b) p5RHH is less efficient than
Lipofectamine 2000 when transfecting plasmid DNA. (Scale bar = 50 µm)

efficiency achieved in vitro, difficulties with cytotoxicity at high nanoparticle concentrations
reflect the challenges that accompany traditional cationic lipid transfection agents. In the present
work, we have modified melittin peptides to achieve high efficiency siRNA transfection based
on the hypothesis that melittin’s membrane disrupting capacity would provide a novel means of
overcoming endosomal entrapment, which is a key drawback to previously reported CPP-based
siRNA transfection agents.26, 29, 35
Indeed our experiments confirm that melittin derivatives are able to transfect siRNA into
B16-F10 cells. Analysis of the peptide sequences reveals that addition of histidine residues
appears to play a role in the ability of peptides to deliver siRNA. Notably, introduction of a
histidine residue into the sequence of p5RWR enables knockdown, while adding a second
histidine to p5RH improves its transfection capacity. While the exact function of these histidine
residues is not clear, their importance is evident based on our peptide screening.67, 68
Other modifications intended to improve siRNA transfection were based on increasing
the lytic capacity of the peptide. Interestingly, acid-activatable full-length melittin has
demonstrated effective endosomal disruption, suggesting that even cytotoxic melittin can be
harnessed to promote siRNA entry into the cytoplasm.69, 70 Consequently, we tested two
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additional melittin derivatives with longer N-terminal hydrophobic tails, which were expected to
improve lysosomal disruption: p5RH-LL and p5RH-AA.71 Our results reveal that only p5RH-LL
exhibited minimal transfection capacity. It is possible that the lack of transfection by these
variants is attributable to poor nanoparticle stability. Specifically, nanoparticles produced by the
incubation of these melittin derivatives with siRNA may experience accelerated aggregation due
to increased hydrophobic interactions driven by a longer N-terminal tail. Notably, p5RH-LL
exhibits the ability to participate in leucine zipper formation and manifests an average particle
size of 1,061 nm after a 20-minute incubation, whereas p5RH-AA cannot partake in leucine
zipper formation and has an average size of 455 nm, indicating that the hydrophobic N-terminus
of the peptide may be driving particle aggregation.
In conjunction with these data, are detailed analysis of particle size and zeta potential at
varying p5RHH/siRNA ratios. These data reveal that particle size is dependent on zeta potential,
causing particles of increasing surface charge to exhibit smaller average particle sizes. When
combined with the effects of peptide hydrophobicity, a model emerges in which electrostatic
repulsion stabilizes nanoparticles against aggregation driven by hydrophobic interactions. That
p5RHH/siRNA nanoparticles tend to aggregate over time is not surprising in view of the low
magnitude of the zeta potential. Traditionally, colloids are not expected to be stabilized by
electrostatic repulsion unless the magnitude of the zeta potential is over 30 mV. Nonetheless, the
minimal surface charge achieved (+12 mV) is strong enough to slow aggregation, allowing them
to be stabilized by coating with serum proteins. With these methods, stable nanoparticles can be
produced in a reproducible manner.
The ability of p5RHH to deliver siRNA to the cytoplasm yields a quantifiable decrease in
GFP expression at concentrations as low as 10 nM. However, p5RHH is still unable to attain the
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level of transfection efficiency provided by Lipofectamine 2000 in B16-F10 cells. Specifically,
Lipofectamine 2000 appears to be able to deliver higher levels of siRNA to the cytoplasm at high
concentrations (200 nM) as well as low concentrations (10 nm). The lack of improved siRNA
transfection by p5RHH at high concentrations may indicate saturation of the uptake pathway and
limited entry of p5RHH/siRNA nanoparticles compared to lipid-based transfection. In addition, a
drop-off in efficiency relative to Lipofectamine 2000 at low concentrations may be a reflection
of the heterogeneous nanoparticle population. Because nanoparticle formulations are likely to
contain a population of large inactive aggregates, these formulations may contain a considerable
amount of siRNA, which is no longer available for transfection, limiting transfection at low
concentrations.
Nevertheless, p5RHH exhibits a substantial improvement over traditional cationic lipidbased transfection in regards to cytotoxicity, exhibiting a minimal decrease in cell viability at all
tested concentrations. These findings, combined with the stability of these particles in the
presence of serum proteins, imply that p5RHH/siRNA nanoparticles would be a good test
candidate for in vivo delivery of siRNA to intravascular targets or to diseased tissue
characterized by endothelial barrier dysfunction.
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Chapter 3
p5RHH Enables pH-Triggered siRNA
Release and Endosomal Disruption
3.1 Abstract
Characterizing the mechanism of action responsible for siRNA transfection is crucial to
understanding the obstacles that decrease the efficiency of siRNA delivery. Based on previous
characterization of peptide transduction domains, endosomal entrapment is thought to be the
primary barrier diminishing the performance of peptide vectors. Melittin derivatives are
hypothesized to overcome this barrier by safely disrupting endosomal membranes. Our studies
reveal that p5RHH/siRNA nanoparticles are indeed endocytosed by macropinocytosis and
trafficked to acidified endosomal compartments. A lack of transfection in the presence of
chemical inhibitors blocking vacuolar ATPases points to endosomal acidification as a crucial
trigger for successful siRNA delivery to the cytoplasm. In fact, endosomal pH (pH ~4 to 5)
causes p5RHH/siRNA nanocomplex disassembly with p5RHH and siRNA release. Released
peptide is capable of initiating hemolysis at low pH indicating the potential to disrupt endosomal
membranes in vivo. Conversely, a non-functioning melittin derivative, p5RWR, does not respond
to pH and cannot induce knockdown even when endosomal disruption is initiated by
chloroquine. Taken together, these studies suggest that the ability of p5RHH to release siRNA
and disrupt membrane bilayers at low pH is critical for siRNA transfection. Moreover, these
findings delineate general principles regarding nanocomplex responses to endocytosis, which
may guide the development of peptide vectors for siRNA transfection.
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3.2 Introduction
The use of peptides for siRNA transfection requires careful study of their mechanism of
action, given their decreased siRNA transfection efficiency compared to lipids and polymers. By
understanding their limitations, peptides can be better designed to function as transfection agents
while maintaining their low level of cytotoxicity.1-9 Despite initial excitement regarding direct
translocation of CPP-cargo conjugates through the plasma membrane,10-12 the utility of CPPs for
delivery of therapeutic cargo has diminished after follow-up studies revealed that these findings
were a result of fixation artifacts or an occurrence found only at high (~µM) CPP
concentrations.13-17 In fact, uptake of CPPs has been shown to rely on energy-dependent
endocytic mechanisms including macropinocytosis, clathrin-mediated endocytosis (CME), and
caveolae-mediated endocytosis (CvME).18-21 Moreover, endocytosis of CPP-cargo conjugates
can change depending on the cell type in question or the cargo conveyed by the CPP.22, 23
Despite these uncertainties, it appears that there may be a few rules that contribute to the
uptake of siRNA packaged with poly-basic peptides.24, 25 First, arginine-containing peptides have
been shown to interact nonspecifically with plasma membranes through bidentate ionic
interactions with cell surface proteoglycans such as heparan sulfate (HSPG) with decreased
uptake after cells were treated with heparanase III.26, 27 Moreover, comparison of peptides
enriched for lysine or arginine reveal that the stronger interaction of arginines with HSPGs
promotes increased endocytosis of arginine-containing peptides versus lysine-containing
peptides.28 Second, arginine-containing peptides are able to initiate actin reorganization via Rac
activity upon binding to HSPGs on cell surfaces.21, 29 This behavior explains the finding that
arginine-containing peptides are able to induce active endocytosis via standard endocytic routes.
Finally, the role of active endocytosis necessitates that peptides and their cargos are likely
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shuttled through the endosomal pathway and ultimately trapped in the endosomal compartment
with low levels of cytoplasmic release.30-34
The challenges associated with endosomal entrapment of therapeutic siRNA when
delivered via peptides has been quantified by Veldhoen et al., who show that transfection
mediated by the peptide, MPGα, requires nearly two orders of magnitude more siRNA per cell to
achieve the same levels of knockdown as more efficient lipid-based transfection.14 Also, despite
often being overlooked, siRNA release from the vector is another aspect of transfection that is
crucial to successful mRNA degradation. For example, double-stranded RNA binding domains
(dsRBD) are able to bind siRNA with high affinity and, despite high levels of cellular uptake,
continue to lack significant protein knockdown when treated with chloroquine.35 These results
are explained by a lack of siRNA release from dsRBD even when cytoplasmic access is provided
by chloroquine-mediated endosomolysis. For a peptide formulation to achieve maximal mRNA
degradation from the packaged siRNA, peptides must promote cellular entry and coordinate
siRNA release with endosomal disruption.
In this chapter, we demonstrate that melittin-derived peptide, p5RHH, exhibits efficient
siRNA transfection based on its ability to coordinately trigger both nanoparticle disassembly and
endosomal disruption upon exposure to endosomal pH. Moreover, it is clear from comparisons
with non-functioning melittin derivatives that endosomal disruption alone does not result in
successful induction of RNAi but requires concurrent siRNA release from the vector. The ability
of p5RHH to coordinate these processes leads to efficient siRNA-mediated GFP silencing that is
not improved by co-incubation with chloroquine. Our results offer general parameters that yield
efficient siRNA delivery into the cytoplasm by peptide vectors, which may aid the development
of non-covalent peptide vectors for improvement of siRNA therapeutics.
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3.3 Materials and Methods
3.3.1 Preparation of Peptide/siRNA Complexes
Melittin derivatives were synthesized by Genscript (Piscataway, NJ), dissolved at 10 mM
in RNase/DNase free water (Sigma, St. Louis, MO) and stored in 4 µL aliquots at -80˚C before
use. p5RHH/siRNA transfection complexes were prepared as described in Chapter 2.
3.3.2 Cell Culture
B16-F10 (ATCC, Manassas, VA) cell lines were maintained under standard cell culture
conditions (37˚C and 5% CO2 in a humidified incubator) in DMEM (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Gibco).
3.3.3 Uptake Inhibition by Flow Cytometry
B16-F10 cells in full media (DMEM with 10% FBS) were incubated with
p5RHH/Alexa488-siRNA nanoparticles (25 nM final siRNA concentration), FITC-transferrin (5
µg/mL, Life Technologies) or 70 kDa FITC-dextran (100 µg/mL, Sigma) in the presence or
absence of endocytosis inhibitors or chloroquine (50 mM stock in DI H2O) for 1 hour. After
incubation, cells were washed 3x in PBS trypsinized and resuspended in FACS buffer (HBSS
with 0.2% FBS and 0.5 mM EDTA) for flow cytometry analysis. Endocytosis inhibitors included
EIPA (80 µM, Sigma), filipin (100 µg/mL, Sigma), and PAO (5 µM Sigma).
3.3.4 Confocal Microscopy
B16-F10 cells were cultured on glass coverslips overnight before incubation with p5RHH
nanoparticles and appropriate uptake markers for 40 minutes. HSA-coated p5RHH/Cy3-siRNA
nanoparticles were added at a final siRNA concentration of 200 nM in the presence of either 70
kDa FITC-dextran (10 mg/mL) or FITC-transferrin (25 µg/mL). After the incubation, cells were
washed on ice 3x in PBS for 10 minutes and fixed in 4% PFA before mounting on glass slides
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(Vectashield Mounting Medium with DAPI, Vector Labs, Burlingame, CA). Cells were imaged
on a Zeiss Meta 510 (Thornwood, NY).
3.3.5 Analysis of GFP Knockdown
B16-GFP cells were plated at 150,000 cells/well 6-well plates and transfected 12 hours
later at a final concentration of 25 or 50 nM siRNA in 1 mL of 10% DMEM in the presence or
absence of 10 µM bafilomycin A1 (10 mM stock in DMSO, Sigma) or 50 µM chloroquine (50
mM stock in DI H2O). 24 hours after transfection, cells were trypsinized and resuspended in
FACS buffer (0.2% FBS and 0.5 mM EDTA) for flow cytometry or lysed for western blotting.
eGFP siRNA (Sense: 5’-GACGUAAACGGCCACAAGUUC-3’) was purchased from Sigma.
Scrambled siRNA was purchased from Qiagen (Valencia, CA).
3.3.6 siRNA Dye Accessibility at Low pH
Preformed p5RHH/siRNA nanoparticles were incubated in HBSS at the indicated pH for
30 minutes in the presence of TOPRO-3 (Life Technologies) diluted 1 to 1,000. TOPRO-3
fluorescence was measured in a 96-well plate with excitation at 642 nm and emission at 661 nm.
Fluorescence values were then normalized to siRNA-only controls and presented as the average
of three separate experiments.
3.3.7 pH-Dependent Gel-Mobility Assays
p5RHH/siRNA nanoparticles were incubated in HBSS at the indicated pH for 30 minutes
before resolution on a 12% TBE-PAGE gel for 4 hours at 90 V. siRNA was visualized by
staining with SYBR GOLD in 1x TBE (IBIScientific) diluted 1 to 10,000 for 15 minutes.
3.3.8 Acridine Orange Staining for Lysosomal Disruption
B16-F10 cells plated on coverslips were loaded with acridine orange at 1 µM for 15
minutes and washed 3x in PBS before incubation in the presence of p5RHH/siRNA
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nanoparticles in 10% DMEM at a final siRNA concentration of 100 nM for 12 hours.
Alternatively, cells were exposed to chloroquine (Sigma) at 100 µM for 15 minutes prior to
imaging. Live cells were visualized by fluorescence microscopy on an Olympus BX610 (Tokyo,
Japan).
3.3.9 RBC Hemolysis
Rabbit red blood cells (RBC) were isolated from whole blood by centrifugation and
washed in PBS 3x for before storage at 4°C. Prior to hemolysis studies, RBC were washed 3x in
pH-appropriate HBSS and diluted 1 to 5,000. RBC in pH-specific buffer were then incubated
with p5RHH/siRNA nanoparticles for 12 hours. RBC remnants were pelleted by centrifugation,
and the hemoglobin content of the supernatant was measured by UV absorbance at 550 nm.
Absorbance values were then normalized against maximum lysis by p5RHH only controls and
presented as the average of three separate experiments.

3.4 Results
3.4.1 p5RHH/siRNA Nanoparticle Endocytosis via Macropinocytosis
The uptake of peptide/siRNA nanoparticles has been studied in depth and appears to be
vector dependent. For example, in contrast to the majority of published work, Crombez et al.
conclude that CPPs promote direct membrane translocation.36 To clarify the mechanism by
which p5RHH achieves cytoplasmic delivery of siRNA, uptake studies using Alexa488-labeled
scrambled siRNA packaged with p5RHH were performed. Incubation of cells at 4°C results in
near complete inhibition of p5RHH/siRNA uptake removing the possibility that p5RHH
mediates direct membrane translocation for cytoplasmic release of siRNA (Figure 3.1).
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To determine which endocytic pathway is responsible for p5RHH/siRNA nanoparticle
uptake, endocytosis inhibitors were used to block specific uptake pathways. The use of
endosomal inhibitors has been shown to be nonspecific and cell type dependent. Therefore, we
performed uptake inhibition assays for short incubation times (1 hour) at inhibitor concentrations
that did not affect other pathways as demonstrated by inhibition of standard endosomal markers
transferrin (CME) and 70 kDa dextran (macropinocytosis) (Figure 3.2b-g). B16-F10 cells are
known not to express caveolin-1, and uptake of caveolar marker Cholera Toxin B is not
measureable in this cell type (unpublished observation). Use of these inhibitors indicate that
macropinocytosis is the major pathway responsible for p5RHH/siRNA uptake. Macropinocytosis
inhibitor, EIPA, dramatically reduces p5RHH/siRNA uptake whereas the CvME inhibitor,
filipin, and the CME inhibitor, PAO, have no affect on p5RHH/siRNA uptake (Figure 3.2h-j).
Confocal microscopy confirms the flow cytometry data, showing strong colocalization of
p5RHH/Cy3-siRNA with 70 kDa FITC-dextran but not FITC-transferrin (Figure 3.3). Cells were
incubated with uptake markers for only 30 minutes to avoid release of Cy3-labeled siRNA into
the cytoplasm, which could yield cytoplasmic or nuclear fluorescence that would confound the
analysis of these experiments. Cells exhibiting cytoplasmic release were not imaged to avoid
these issues. Interestingly, rapid uptake and release of Cy3-labeled siRNA in less than one hour
points to the efficient endosomal escape provided by p5RHH/siRNA nanoparticles (unpublished
observation).
3.4.2 Importance of Endosomal Acidification in p5RHH-Mediated Transfection
After endocytosis, the contents of endosomes experience different fates including
recycling to the cell surface, trafficking to specific cellular compartments, or delivery to acidic
lysosomes for degradation. Oftentimes, endocytosed nanoparticles are subject to the latter.
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Figure 3.1 p5RHH/siRNA Nanoparticle Uptake is Temperature Sensitive
Two-hour uptake of p5RHH/siRNA nanoparticles is decreased by incubating cells at 4°C (c) as compared
with 37°C (b).

Figure 3.2 Uptake Inhibition Studies
(a) Flow cytometry analysis of untreated B16-F10 control cells. (b-d) Uptake of CME-specific cargo,
FITC-transferrin, is only inhibited by PAO, a CME inhibitor. (e-g) 70 kDa FITC-dextran, a marker of
macropinocytosis, is only inhibited by EIPA, an inhibitor of macropinocytosis. (h-j) p5RHH/siRNA
nanoparticle uptake is nearly completely abolished by EIPA.
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Figure 3.3 p5RHH/siRNA Nanoparticles Co-localize with FITC-Dextran
Confocal microscopy depicting uptake at 40 minutes (200 nM final siRNA concentration) reveals no
colocalization of p5RHH/siRNA nanoparticles (b) with FITC-transferrin (c-d), but confirms endocytosis
by macropinocytosis along with FITC-dextran (e-f). (Scale bar = 10 µm)

Fortuitously, the change in pH along the endosome/lysosome pathway can provide a trigger for
particle disassembly and siRNA release. The pH of endosomes and lysosomes is tightly
controlled by acidification via membrane-bound vacuolar ATPases, reaching values as low as
4.5.37 To determine if the low pH generated by these vacuolar ATPases is involved in siRNA
release from the endosome, cells were incubated in the presence of Bafilomycin A1 during the
overnight transfection to inhibit endosomal acidification. Compared with control cells
transfected without Bafilomycin A1, Bafilomycin A1-treated cells demonstrated a near complete
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loss of GFP knockdown as determined by flow cytometry (Figure 3.4d-f). Since Bafilomycin A1
could be slowing p5RHH/siRNA uptake, flow cytometry examining the uptake of fluorescently
labeled siRNA in B16-F10 cells was utilized to ensure that the concentration of Bafilomycin A1
used in these assays did not block p5RHH/siRNA uptake (Figure 3.4a-c). These data confirm the
importance of endosomal acidification as a trigger for the cytoplasmic release of siRNA when
delivered to cells via p5RHH.
3.4.3 Acidic pH Triggers Nanoparticle Disassembly
Since endosomal acidification is crucial for the ability of p5RHH to deliver siRNA to the
cytoplasm, p5RHH/siRNA nanoparticles were incubated at decreasing pH to ascertain how an

Figure 3.4 Endosomal Acidification is Critical for p5RHH-Mediated Transfection
(a-c) p5RHH/Alexa488-siRNA nanoparticle uptake after 1 hour (b) is not altered by treatment with
Bafilomycin A1 (c). (d-f) Bafilomycin A1 drastically reduces GFP knockdown (f) compared to cells
transfected in the absence of Bafilomycin A1 (e).
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increasingly acidic environment affects nanoparticle integrity. Dye-binding assays using the
nucleic acid stain TOPRO-3 reveal that siRNA becomes increasingly accessible at pH ≤ 5.5 as
witnessed by an increase in TOPRO-3 fluorescence (Figure 3.5a). Control samples were
analyzed to show that TOPRO-3 binding to siRNA is not affected by pH in this range
(unpublished observation). To determine if increased dye accessibility was correlated with
increased siRNA release, additional samples were run on a 12% polyacrylamide gel to resolve
free siRNA (Figure 3.5b). Based on these gels, it is apparent that siRNA does not become free to
migrate into the gel until a pH of 4.5 is achieved. Taken together, these assays reveal a strong
pH-dependent mechanism for both particle disassembly and siRNA release with a lower pH (4.5)
required for siRNA to be completely released than that required to initiate particle disassembly
(pH = 5.5).
Interestingly, p5RWR, a non-functioning melittin derivative lacking histidine residues
among other differences, does not respond to acidic pH. In contrast to p5RHH, p5RWR does not
demonstrate an increase in TOPRO-3 fluorescence at pH ≤ 5.5 (Figure 3.5a) and lacks siRNA
release as measured by gel mobility (Figure 3.5b). These data suggest that the ability of
p5RHH/siRNA nanoparticles to disassemble in response to low pH may be crucial for successful
siRNA transfection.
To corroborate nanoparticle disassembly, pH-dependent p5RHH release from
p5RHH/siRNA nanoparticles was quantified using dialysis through a 10K dialysis membrane
(Figure 3.5c). These assays reveal that approximately 40% of p5RHH remained free after
particle assembly with a strong release of p5RHH at pH ≤ 5.5. This pH dependence matches the
pH dependence seen for siRNA dye binding, which supports the finding that acidic pH triggers
nanoparticle disassembly and subsequent release of both p5RHH and siRNA.
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3.4.4 Release of Free p5RHH at Low pH Lyses Membrane-Bound Vesicles
The importance of p5RHH release from these nanoparticles is first determined in vitro
using RBC hemolysis assays. When incubated at decreasing pH, the ability of p5RHH/siRNA
nanoparticles to lyse RBC becomes enhanced at pH ≤ 5.5 (Figure 3.5d). These assays were
performed at 4°C to decrease the rate of auto-hemolysis seen at higher temperatures. RBC
hemolysis indicates that liberated p5RHH can lyse membrane-bound structures and could
potentially disrupt endosomal membranes in intact cells. Endosomal disruption was studied in
tissue culture using acridine orange staining. Cells were first loaded with acridine orange, which
fluoresces red at low pH in the endosome and green in the cytoplasm (Figure 3.5e). Endosomal
disruption can be visualized by an increase in cytoplasmic green fluorescence as demonstrated in
cells incubated in the presence of 100 µM chloroquine (Figure 3.5f). Similarly, cells transfected
with p5RHH/siRNA also released acridine orange from endosomal vesicles, confirming
endosomal disruption (Figure 3.5h). Alternatively, cells treated with p5RWR/siRNA did not
exhibit acridine orange release, confirming that a lack of particle disassembly prevents release of
membrane-lytic peptide and therefore endosomolysis (Figure 3.5g).
3.4.5 Nanoparticle Disassembly Enables siRNA Delivery to the Cytoplasm
As noted in Chapter 2, p5RHH is less efficient than traditional lipid transfection agent
Lipofectamine 2000. When considering sources of inefficiency, p5RHH may also suffer from
endosomal entrapment, especially at low concentrations, when the amount of endocytosed
peptide may be too low to allow efficient endosomal escape. However, transfection of B16-GFP
cells in the presence of chloroquine provides no benefit over transfection in the absence of
chloroquine at doses from 10 nM to 200 nM (Only 50 nM siRNA is shown, Figure 3.6a).
Confocal microscopy confirms cytoplasmic release of Cy3-labeled oligonucleotides when
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Figure 3.5 pH Mediates p5RHH/siRNA Nanoparticle Disassembly and Endosomolysis
(a) TOPRO-3 dye-binding assays reveal increased siRNA accessibility at pH ≤ 5.5 when packaged by
p5RHH but not p5RWR. (b) Gel-mobility assays reveal siRNA release from p5RHH but not p5RWR at
low pH. (c) p5RHH release from p5RHH/siRNA nanoparticles as measured by dialysis and UV
absorption is increased at low pH. (d) Hemolysis by p5RHH/siRNA nanoparticles increases at pH ≤ 5.5.
(e-h) Acridine orange release assays exhibit increased endosomolysis and cytoplasmic green fluorescence
12 hours post-transfection when treated with 100 µM chloroquine (f) and p5RHH/siRNA nanoparticles
(final siRNA concentration 100 nM) (h) but not p5RWR/siRNA nanoparticles (g). (Scale bar = 50 µm)
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Figure 3.6 p5RHH Mediates Both siRNA Release and Endosomal Escape
(a) Knockdown of GFP by p5RHH (50 nM final siRNA concentration) is not increased by co-incubation
with 50 µM chloroquine, whereas p5RWR shows a minor improvement in knockdown. (b) p5RWR and
p5RHH mediate similar levels of siRNA uptake. (c) Confocal microscopy 24 hours post-transfection
reveals that Cy3-labeled oligos (at 100 nM) remain in punctate vesicles when transfected by p5RWR. (d)
Chloroquine co-incubation yields cytoplasmic distribution of Cy3-labeled oligos when transfected by
p5RWR. (e) p5RHH alone mediates cytoplasmic delivery of siRNA. (f) Chloroquine co-incubation does
not alter oligo delivery by p5RHH. (Scale bar = 10 µm)

transfected by p5RHH with no impact of chloroquine co-incubation (Figure 3.6e,f). Alongside in
vitro siRNA release and acridine orange assays, these data underscore the relationship of pHmediated nanoparticle disassembly with effective siRNA delivery to the cytoplasm and suggest
that inefficiencies in p5RHH-mediated transfection are not associated with endosomal
entrapment.
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Despite nearly equivalent uptake of siRNA (Figure 3.6b), p5RWR/siRNA nanoparticles
are unable to initiate silencing of GFP as determined by FACS (Figure 3.6a). Analysis of
p5RWR by confocal microscopy (Figure 3.6c) confirms that oligonucleotides packaged with
p5RWR do not reach the cytoplasm without co-incubation in the presence of 50 µM chloroquine
(Figure 3.6d). Interestingly, p5RWR/siRNA nanoparticles only exhibit a minimal increase in
transfection when co-incubated with chloroquine (Figure 3.6a), despite the dramatic increase in
cytoplasmic localization observed by confocal microscopy. This continued lack of transfection
could be explained by poor access of siRNA to the RISC due to continued binding to p5RWR.
This possibility is supported by a lack of particle disassembly witnessed during in vitro dyebinding and gel-mobility assays, highlighting that nanoparticle disassembly is not only crucial
for the release of peptide and endosomolysis but also for siRNA to initiate RISC assembly.

3.5 Discussion
Clarifying the mechanism of action underlying peptide-based siRNA transfection is
crucial for understanding the high efficacy of siRNA transfection provided by p5RHH as well as
identifying potential sources of inefficiency which might affect p5RHH-mediated siRNA
delivery.14 In the past, peptides have been shown to mediate direct translocation of siRNA
through the plasma membrane. However, recent work supports the involvement of active uptake
of peptide/siRNA particles via endocytosis.14 While the specific pathway may be cell type and
vector dependent, the majority of peptides appear to mediate endocytosis via macropinocytosis.30
In a similar fashion, the current work demonstrates that p5RHH-mediated transfection
does not rely on direct penetration of the plasma membrane as witnessed by a decrease in
p5RHH/siRNA nanoparticle uptake at 4°C. Alternatively, the sensitivity of p5RHH/siRNA
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nanoparticle uptake to macropinocytosis inhibitors but not clathrin-mediated uptake inhibitors
suggests that p5RHH-mediated transfection is dependent on fluid phase macropinocytosis for
cell entry. Detailed analysis of the uptake of cationic peptides provides insight into the
macromolecular interactions that may contribute to this process. Specifically, arginine residues
can form electrostatic interactions with cell surface proteoglycans, which results in close
association with the plasma membrane.25 The robust uptake of positively charged peptides
indicates that electrostatic association with the plasma membrane and subsequent fluid phase
uptake is sufficient to achieve substantial peptide/siRNA uptake. Nevertheless, the ability of
cationic peptides to interact with cell surface receptors such as CXCR4 reveals that further
studies are required to clarify the initial interactions responsible for p5RHH/siRNA nanoparticle
association with the plasma membrane.38
Proper siRNA trafficking subsequent to the initial endocytic event is also vitally
important for successful siRNA transfection. In particular, previous work has shown that siRNA
transfection requires the coordination of both siRNA release and endosomal escape.39 Premature
siRNA release in the endosome allows siRNA degradation by endosomal hydrolases. On the
other hand, peptides which bind too strongly to siRNA are also hypothesized to prevent
successful RNAi.35 Consequently, siRNA release from peptide transfection agents must be
concurrent with endosomal escape for maximal mRNA knockdown. We have designed our
melittin derivatives to release siRNA based on protonation of histidine residues in the siRNA
binding portion of p5RHH. These modifications are expected to induce particle disassembly and
release of lytic melittin derivatives to aid endosomolysis. A lack of transfection in the presence
of Bafilomycin A1 demonstrates the importance of endosomal acidification in the transfection of
siRNA by p5RHH.
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Indeed, dye-accessibility assays and siRNA release as monitored by gel retardation
assays reveal that acidification triggers particle unpackaging with release of membrane-active
peptides. The release of p5RHH was quantified and displays the same pH dependence with
increased peptide release at pH ≤ 5.5. Importantly, this pH dependence was also seen when
studying RBC hemolysis, suggesting that release of free peptide plays a role in membrane
disruption. These studies also point out a potential source of inefficiency. Particle disassembly
and hemolysis begin at a pH of 5.5, before siRNA is completely released at a pH of 4.5. If
endosomal disruption occurs before complete siRNA release from p5RHH, not all of the
delivered siRNA will be accessible to the RISC. This possibility necessitates a more detailed
biophysical characterization of siRNA release from p5RHH/siRNA nanoparticles. Nonetheless,
it is clear that p5RHH demonstrates a key characteristic required for efficient cytoplasmic
delivery of siRNA: the ability to coordinate siRNA release with concurrent endosomal
disruption.
Histidine protonation has often been used as a trigger for siRNA delivery in the context
of the proton sponge effect, in which various strategies have taken advantage of histidine’s
buffering capacity to neutralize endosomal acidification, leading to osmotic rupture of the
endosome due to the accumulation of Cl- counterions.32, 40-44 Moreover, histidine appears to be an
ideal buffering agent due to a lack of pKa changes when non-specifically associated with nucleic
acids.45 While p5RHH also relies on histidine protonation as a trigger for siRNA release, the
mechanism of endosomal escape appears to be direct membrane lysis rather than osmotic
disruption. In comparison with methods relying on endosomal buffering for osmotic rupture, the
presence of only two histidine residues in our peptide suggest that p5RHH does not have the
buffering capacity to rely on the proton sponge effect for endosomal escape. As an example, Lo
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and Wang have shown that at least ten histidine residues are required for successful cytoplasmic
release of DNA when transfected by TAT.32
While we cannot completely rule out a contribution of the proton sponge effect to the
endosomolysis seen via acridine orange release, our data indicate that endosomal acidification
triggers particle disassembly and release of membrane-lytic peptide to promote endosomolysis.
The unique ability of p5RHH/siRNA nanoparticles to efficiently coordinate these events
portends potential for the use of p5RHH-mediated transfection in a variety of cell types.
Furthermore, analysis of p5RHH’s mechanism of action provides insight that can guide the
further development of future peptide vectors for siRNA transfection.
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Chapter 4
Therapeutic Potential for Melittin-Derived siRNA Nanocarriers
4.1 Abstract
Despite the many diseases potentially treatable by siRNA therapeutics, the clinical
application of siRNA to the treatment of disease is effectively limited by nanoparticle
pharmacokinetics. Due to poor extravasation through continuous endothelium, penetration of
siRNA-carrying nanoparticles into most diseased tissues is severely limited, suggesting that only
vascular/hematologic diseases or diseases characterized by disrupted endothelial barriers can be
targeted with current siRNA delivery technology. Such diseases include tumors, sites of
angiogenesis, atherosclerosis, and leukemia. Initial studies regarding siRNA delivery in relevant
tissue culture models indicate that p5RHH is able to safely and efficiently mediate siRNA
transfection in multiple cell types that are traditionally considered to be difficult to transfect.
These cell types include primary human umbilical vein endothelial cells, macrophages, and
lymphocytes. In most cell types, comparison with Lipofectamine 2000 indicates that p5RHH is
less effective, but p5RHH is equally potent when transfecting the RAW264.7 macrophage cell
line. The potential utility of siRNA is best illustrated in the therapy of HTLV-1-induced ATLL in
which NFκB activation has been shown to mediate immortalization. Due to the complexity of
NFκB signaling, small molecule inhibitors have only been able to block its activation but not its
action. Given the complicated nature of NFκB activation in vivo, these small molecules may be
of limited utility, highlighting a need for new therapeutics. Initial studies using p5RHH/siRNA
nanoparticles reveal the ability to simultaneously transfect p65 and p100/p52 siRNAs into a
model of ATLL leading to blockade of both canonical and non-canonical NFκB signaling for a
strong suppression of ATLL viability. Initial in vivo studies suggest that p5RHH is able to
localize to ATLL tumors in a spontaneous murine model of the disease with clearance mediated
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by the kidneys. These initial data are suggestive of potential for tumor suppression, warranting
further in vivo characterization of p5RHH/siRNA nanoparticle stability and efficacy.

NOTE: Portions of this chapter are adapted from previously published work.
Hou, K.K.; Pan, H.; Lanza, G.M.; Wickline, S.A., Melittin derived peptides for nanoparticle
based siRNA transfection. Biomaterials 2013, 34 (12), 3110-3119.
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4.2 Introduction
From a theoretical standpoint, siRNA has the potential to be useful in a variety of
diseases, most notably cancer, inflammation and atherosclerosis, where pathology can be
attributed to a handful of specific proteins. Unfortunately, the utility of siRNA in clinical
situations is limited by poor biodistribution as a consequence of their packaging into
nanoparticles. While nanoparticles are expected to improve circulation half-lives and enable
targeted delivery to diseased tissues, these drug delivery paradigms are difficult to achieve in
practice. In reality, the tissue distribution of nanoparticle therapeutics is not determined by
targeting ligands on their surface, but by vascular architecture and cellular composition.
For example, nanoparticles tend to deposit in the organs of the reticulo-endothelial
system (RES), which includes the liver, spleen, and bone marrow. Based on the specialization of
their vascular architecture, sinusoids in the spleen and bone marrow filter and capture
nanoparticles larger than 200 nm. On the other hand, fenestrae in the liver endothelium allow
particles less than 100 nm to pass through and enable hepatocyte or macrophage uptake.1 While
tissue architecture often determines nanoparticle accumulation, nanoparticle uptake is
determined by cellular composition. For instance, macrophages in the spleen, lung, and liver tend
to phagocytose the majority of nanoparticles deposited in those tissues due to their natural
function in clearance of cellular debris and extracellular pathogens. Interestingly, active targeting
of nanoparticles by incorporating targeting moieties on the nanoparticle surface has been shown
to improve uptake into desired cells after extravasation, although active targeting does not affect
biodistribution and tissue accumulation.2
Based on these findings, it is clear that pathologies targetable by siRNA-carrying
nanoparticles must occur in the blood stream or exhibit a discontinuous endothelial barrier to
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allow nanoparticles to escape the vasculature and enter the tissue. In this chapter, we establish
proof of concept for the utility of p5RHH/siRNA nanoparticles in the treatment of such diseases.
Examples include solid tumors, which are often invested by newly formed blood vessels
characterized by poorly formed basement membranes and a lack of supporting pericytes, states
of severe atherosclerosis, which are characterized by discontinuous endothelial barriers,
inflammatory conditions in which angiogenic vessels participate in disease progression, and
hematologic malignancies such as leukemia.3, 4

4.3 Materials and Methods
4.3.1 Cell Culture
B16-F10 and RAW264.7 (ATCC, Manassas, VA) cell lines were maintained under
standard cell culture conditions (37˚C and 5% CO2 in a humidified incubator) in DMEM (Gibco,
Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco). F8 cells from the Ratner lab
were maintained in 10% RPMI (Gibco). Human umbilical vein endothelial cells (HUVECs) were
purchased from Lifeline Technologies (Frederick, MD) and cultured in VascuLife Basal Medium
(Lifeline Technologies) supplemented with 5 ng/mL EGF, 5 ng/mL bFGF, 15 ng/mL IGF-1 , 50
µg/mL ascorbic acid, 1 µg/mL hydrocortisone hemisuccinate, 0.75 U/mL heparin sulfate, 10 mM
L-glutamine, and 2% fetal bovine serum in accordance with manufacturer instructions. For all
experiments, HUVECs were used at passage three.
4.3.2 siRNA Transfection
Cells were plated in 6-well plates 12 hours before transfection and cultured under
standard cell culture conditions. p5RHH/siRNA nanoparticles were prepared and incubated with
cells for 4 hours in a final volume of 1 mL Optimem I (Gibco) or appropriate media
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supplemented with 10% FBS. Transfections were scaled accordingly for cells plated in 12-well
plates based on cell culture surface area. After transfection, cells were washed twice with PBS
and incubated with standard cell culture medium for another 24 to 72 hours before analysis.
Lipofectamine 2000 was used in accordance with the manufacturer’s protocol. siGENOME
mouse MAPK9 siRNA1, siGENOME mouse STAT3 siRNA2, siGENOME human STAT3
siRNA2, siGENOME mouse NFΚB (p65) siRNA5, and siGENOME mouse NFΚB2 (p100/p52)
siRNA1 were purchased from Dharmacon (Lafayette, CO). Scrambled siRNA was purchased
from Qiagen (Valencia, CA).
4.3.3 Western Blotting
24 or 48 hours after transfection, 100 to 200 µL RIPA buffer (10 mM Tris–HCl (pH 7.5),
150 mM NaCl, 1.0% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
1 mM EDTA, 5% glycerol) with 1 mM PMSF and Complete Protease Inhibitor Cocktail (Roche)
was added to each well of a 6-well plate and incubated on ice for 1 hour. Cell lysates were then
centrifuged at 4˚C for 5 minutes and supernatants stored at -20˚C. Lysates were resolved on
Nupage Bis-Tris gels (Life Technologies) and transferred to 0.22 µm nitrocellulose before
blocking in 5% bovine serum albumin (Sigma) in TBS-T. Primary antibodies used included
rabbit anti-GAPDH (1:1,500, Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-β-actin
(1:1,000, Sigma), mouse anti-STAT3 (1:1,000, Cell Signaling, Danvers, MA), rabbit anti-JNK2
(1:1,000, Cell Signaling), rabbit anti-p65 (1:1,000, Cell Signaling), rabbit anti-p100 (1:1,000,
Cell Signaling). Secondary antibodies used included anti-rabbit HRP (1:5,000, Santa Cruz
Biotechnology) and anti-mouse HRP (1:5,000, Santa Cruz Biotechnology). Blots were developed
using ECL Western Blotting Substrate (Pierce, Rockford, IL). Representative western blots are
presented herein.
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4.3.4 Real-Time PCR
24 hours after transfection, cDNA was produced using the FastLane Cell cDNA kit
(Qiagen). cDNA was stored at -20˚C until use. mRNA levels were quantified on an Applied
Biosystems 7300 System (Applied Biosystems, Carlsbad, CA) using iTaq SYBR green with
ROX (Bio-Rad, Hercules, CA). Quantitect Primer Assay (Qiagen) provided gene-specific
primers for each gene. Genes of interest were normalized to species-appropriate β-actin. Results
are reported as the average “fold change” relative to untreated controls for three separate
experiments.
4.3.5 Cell Viability Assay
Cell viability was determined 72 hours post-transfection using Alamar Blue (Life
Technologies). Briefly, Alamar Blue was diluted 1 to 10 into phenol red-free media and
incubated with cells for 2 to 4 hours. Fluorescence was measured on a fluorescent plate reader
with excitation at 570 nm and emission at 585 nm (Varian Cary Eclipse, Agilent Technologies,
Santa Clara, CA).
4.3.6 Tube Formation Assay
Matrigel (BD Biosciences, San Jose, CA) was thawed overnight at 4˚C in an ice bath and
subsequently allowed to gel in 24-well plates for 1 hour at 37˚C. 24 hours after transfection with
STAT3 specific or control siRNA, HUVECs were trypsinized and plated on matrigel at a cell
density of 30,000 cells/well. Tube formation was allowed to proceed for 24 hours before
visualization on an inverted microscope. A tube formation score was determined based on total
tube length per field of view normalized to untreated controls as measured in ImageJ (NIH).
4.3.7 HUVEC Migration Assay
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The bottoms of 12-well transwell inserts with 3.0 µm pore size (Corning, Tewksbury,
MA) were coated with 1% porcine gelatin (Sigma) at room temperature for 1 hour. HUVECs
transfected with STAT3 specific or control siRNA 24 hours in advance were then trypsinized
and resuspended in growth factor-free media and added to the apical transwell chamber at a
density of 30,000 to 50,000 cells/well. The bottom chamber contained growth factor-free
VascuLife basal media ± 5 ng/mL bFGF. Cells were allowed to migrate through the polymer
insert for 12 hours. Un-migrated cells were removed from the apical chamber with a sterile
cotton swab, and migrated cell numbers were determined via Alamar Blue. Data are presented as
the average normalized migration from 3 separate experiments. For visualization, inserts were
cut out and mounted on glass slides. Cell nuclei were visualized with DAPI staining on an
Olympus BX610 (Tokyo, Japan) and reported as average cell number per field of view.
4.3.8 Foam Cell Formation Assay/Oil-Red O Staining
48 hours after transfection with JNK2 specific or control siRNA, RAW264.7 cells were
incubated ± 50 µg/mL Ac-LDL (Intracel, Frederick, MD) for an additional 24 hours. Cells were
then stained with Oil-Red O to visualize foam cell formation. Briefly, Oil-Red O was dissolved
in neat methanol (5 mg/mL) overnight before filtration through a 0.22 µm filter. The Oil-Red O
stock was then diluted 3 to 5 in distilled water to make up the Oil-Red O working solution and
filtered a second time through a 0.22 µm filter. Cells were fixed in 4% PFA for 10 minutes at
room temperature and washed with 60% methanol before staining in the Oil-Red O working
solution for 15 minutes. After staining, cells were washed once with 60% methanol and once
with distilled water before mounting on glass slides.
4.3.9 Animal Experiments
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Experimental animal protocols were approved by the Animal Care Committee of
Washington University School of Medicine. Transgenic mice with spontaneous tumors were a
gift from the Ratner lab.5 Mice with advanced tumors were selected for pilot experiments and
injected with a single dose at 1 mg/kg 24 hours before sacrifice. Animals were perfused with
saline, and tumors were excised for IVIS imaging and frozen sectioning.

4.4 Results
4.4.1 STAT3 siRNA Delivery to Slow Melanoma Growth
Signal Transducer and Activator of Transcription 3 (STAT3) is a well-known oncogene
believed to play a critical role in a wide variety of human malignancies.6, 7 To test the ability of
p5RHH to knockdown constitutively activated oncogenes, we targeted STAT3 expression in
B16-F10 cells which are known to be STAT3 dependent.8 Delivery of a STAT3-specific siRNA
led to degradation of STAT3 mRNA with a subsequent decrease in STAT3 protein levels
(p5RHH IC50: ~50 nM, Lipofectamine 2000 IC50: ~10 nM) (Figure 4.1). p5RHH-mediated
STAT3 siRNA transfection led to decreased B16-F10 viability (60% at 200 nM) 72 hours
following transfection as determined by Alamar Blue assays (Figure 4.1f). Importantly,
scrambled siRNA showed no effect on B16-F10 viability, illustrating the safety of p5RHH in
comparison to Lipofectamine 2000 (Figure 4.1c), which produced an equivalent decrease in cell
viability (up to 60% at 200 nM) when delivering either STAT3-specific or scrambled siRNAs,
highlighting the improved cytotoxicity profile provided by p5RHH.
4.4.2 STAT3 siRNA Delivery to Decrease Angiogenesis
Pathological angiogenesis is a hallmark of many disease states, including cancer,
atherosclerosis, and inflammation. STAT3 has previously been shown to be a key mediator in the
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Figure 4.1 Knockdown of STAT3 in B16-F10 Cells
Lipofectamine mediates STAT3 knockdown with an IC50 of 10 nM as determined by western blotting (a)
and RT-PCR (b) but is unable to mediate a STAT3-specific decrease in cell viability due to non-specific
cytotoxicity (c). p5RHH mediates sequence-specific knockdown of STAT3 with an IC50 of 50 nM as
determined by western blotting (d) and RT-PCR (e) resulting in a STAT3-dependent decrease in cell
viability 72 hours post-transfection (f).
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migration and maturation of endothelial cells during angiogenesis.9-12 Therefore, we delineated
the ability of p5RHH to deliver STAT3 siRNA to HUVEC cells for the blockade of angiogenesis
in vitro with the use of matrigel tube formation assays and transwell cell migration assays.
HUVECs transfected with p5RHH/STAT3 siRNA nanoparticles exhibited a decrease in STAT3
mRNA and protein levels with an IC50 of ~50 nM (Figure 4.2d,e) without any accompanying
decrease in HUVEC viability (Figure 4.2f). As with transfection of B16-F10 cells,
Lipofectamine 2000-mediated transfection exhibits an IC50 of ~10 nM by western blotting but
causes cytotoxicity with a 40% decrease in cell viability at siRNA doses as low as 25 nM (Figure
4.2a-c).
Although p5RHH-mediated STAT3 siRNA transfection did not impact cell viability,
p5RHH/STAT3 siRNA nanoparticle treatment of HUVECs manifested a ~60% decrease in tube
formation as compared to scrambled siRNA (Figure 4.3a,b). In addition, migration of HUVECs
transfected by p5RHH was reduced by 50% as quantified by Alamar Blue (Figure 4.3d) and
fluorescence microscopy (Figure 4.3c). These data demonstrate the high efficiency with which
p5RHH is able to safely transfect primary human endothelial cells for the prevention of
pathological angiogenesis.
4.4.3 JNK2 siRNA Delivery to Decrease Foam Cell Formation
The disrupted endothelial barriers that characterize atherosclerotic plaques make
atherosclerosis a prime target for nanoparticle-based therapies.13 To ensure that we could use
p5RHH/siRNA nanoparticles to block foam cell formation, the hallmark of atherosclerotic
plaques, we delivered JNK2 siRNA to RAW264.7 (mouse macrophage cell line) in vitro. JNK2
is a known mediator of foam cell formation and has been implicated in the uptake of both AcLDL by scavenger receptor A as well as oxLDL by CD36.14, 15 p5RHH was able to deliver
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Figure 4.2 Knockdown of STAT3 in HUVECs
Lipofectamine mediates STAT3 knockdown with an IC50 of 10 nM as determined by western blotting (a)
and RT-PCR (b) but induces nonspecific cytotoxicity (c). p5RHH mediates sequence-specific knockdown
of STAT3 with an IC50 of 50 nM as determined by western blotting (d) and RT-PCR (e) without
cytotoxicity (f).
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Figure 4.3 STAT3 Knockdown in HUVECS Decreases Angiogenesis in vitro
STAT3 siRNA decreases tube formation on matrigel by 60% (scale bar = 200 µm) when compared to
controls (a) as quantified by tube formation score (b). STAT3 siRNA transfection also yields a 40%
decrease in HUVEC migration in response to bFGF in transwell migration assays as determined by
microscopy (scale bar = 50 µm) (c) and Alamar Blue assays (d). * p < 0.05
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Figure 4.4 JNK2 Knockdown in Macrophages Decreases Foam Cell Formation
Lipofectamine 2000 decreases JNK2 expression with an IC50 of 10 nM (a) but causes significant
cytotoxicity when transfecting scrambled siRNA (b). p5RHH-mediated transfection has an IC50 of 10
nM (c), leading to a JNK2-specific decrease in RAW264.7 viability (d). Knockdown of JNK2 by
p5RHH/siRNA nanoparticles at a final siRNA concentration of 50 nM (e) shows a strong decrease in
lipid droplet accumulation in RAW264.7 cells compared with cells treated with scrambled siRNA or
untreated controls. (Scale bar = 25 µm)

siRNA to RAW264.7 cells, leading to a strong decrease in JNK2 protein levels at concentrations
as low as 10 nM (Figure 4.4c). Notably, JNK2 siRNA slowed RAW264.7 proliferation rates
while scrambled siRNA had no affect on cell proliferation (Figure 4.4d). In comparison,
Lipofectamine 2000 has a similar IC50 as determined by western blotting (Figure 4.4a) but also
exhibits extensive cytotoxicity (Figure 4.4b). These data show that transfection of RAW264.7
cells by p5RHH appears to be on par with the transfection achieved by Lipofectamine 2000
without the noted cytotoxicity.
Decreased JNK2 protein levels suppressed foam cell formation in RAW264.7 cells that
were incubated in the presence of 50µg/mL Ac-LDL for 12 hours as determined by light
microscopy following Oil-Red O staining (Figure 4.4e). These images show extensive lipid
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droplet accumulation in non-treated controls and scrambled siRNA treated cells but no lipid
droplet accumulation in RAW264.7 cells treated with a JNK2-specific siRNA.
4.4.4 siRNA Delivery to Block NFκB Signaling in ATLL
The F8 model of HTLV-1-induced ATLL provided a cell line of lymphocytic origin,
which has previously been characterized to show a strong dependence on constitutive activation
of both canonical and non-canonical NFκB pathways similar to human disease. siRNAs were
chosen to target the p65 subunit of the canonical pathway and p100/p52 subunit of the noncanonical pathway. Western blotting revealed a dose-dependent decrease in the expression of
both proteins that was not seen when cells were transfected with a scrambled siRNA control
(Figure 4.5a,b).
Alamar Blue assays 48 hours post-transfection suggest that knockdown of these pathways
in vitro is therapeutically relevant, as a strong decrease in cell viability is recorded with both p65
and p100/p52 siRNAs (Figure 4.5c). However, it is clear that blockade of the non-canonical
NFκB pathway with p100/p52 siRNA (IC50 ~100 nM) is superior to blockade of the canonical
pathway (IC50 ~200 nM). Interestingly, when particles were prepared carrying both p65 and
p100/p52 siRNAs together, a synergistic effect on cell viability was recorded (IC50 ~50 nM).
Given the safety of p5RHH in tissue culture, pilot experiments were conducted to
examine tumor localization of p5RHH/siRNA nanoparticles when delivered in vivo. IVIS
imaging and confocal microscopy reveal tumor delivery of Cy5.5-labeled scrambled siRNA
(Figure 4.6) when introduced by tail-vein injection into mice carrying spontaneous ATLL tumors
at a dose of 1 mg/kg. Notably, after 24 hours, no siRNA was seen in traditional clearance organs
such as the liver and spleen, but strong uptake was found in the kidneys (Figure 4.6b). Confocal
microscopy indicates that Cy5.5-siRNA was taken up in the proximal tubules (Figure 4.6f).
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Figure 4.5 NFκB Blockade Decreases ATLL Viability
(a, b) Western blotting demonstrates knockdown of p100/p52 and p65. (c) Alamar Blue assays 48 hours
post-transfection reveal that scrambled siRNA (■) does not affect F8 cell viability. Knockdown of the p65
pathway (▲) has an IC50 of nearly 200 nM. Targeting p100/p52 (●) yields an IC50 of 100 nM.
Simultaneous blockade of both NFkB pathways (u) improves the IC50 to 50 nM.

Figure 4.6 p5RHH Delivers Cy5.5-Labeled siRNA to Tumors and Kidneys
(a,b) Ex vivo IVIS imaging of resected organs indicates delivery of Cy5.5-labeled siRNA to tumors and
kidneys 24 hours after injection at a dose of 1 mg/kg. (c-f) Confocal microscopy confirms siRNA delivery
to the periphery of the tumor (e) as well as the proximal tubules of the kidney (f). (Scale bar = 50 µm)
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4.5 Discussion
Given the size of our nanoparticles (50 to 200 nm), we have targeted disease processes
that do not require vascular extravasation through intact endothelial barriers. Cancer,
angiogenesis, and atherosclerosis are all characterized by a discontinuous endothelial barrier with
enhanced leakage of nanoparticles into the surrounding tissues. Towards the goal of establishing
a basis for future in vivo studies, we have successfully knocked down STAT3 in melanoma cells,
STAT3 in primary endothelial cells, JNK2 in macrophages, and p65 or p100/p52 in ATLL cells
with minimal cytotoxicity. Despite robust transfection in all cells, transfection efficiency appears
to vary by cell type. RAW264.7 macrophages are the easiest to transfect with an IC50 of 25 nM.
Differences in transfection efficiency among cell types is likely partially attributable to variation
in the native ability of each cell to perform macropinocytosis. Given their propensity for fluid
phase uptake as part of their normal function, macrophages likely take up an increased amount of
p5RHH/siRNA nanoparticles compared to other cell types.
Of equal importance is the observation that all tested doses resulted in minimal
cytotoxicity. The safety of p5RHH/siRNA nanoparticles in all tested cell types indicates that
vector-induced toxicity is unlikely to hinder the use of p5RHH in animal studies. Moreover,
p5RHH/siRNA nanoparticles also exhibit size stability and improved siRNA transfection
capacity when incubated in the presence of human serum albumin for 24 hours before
transfection, an issue which has been acknowledged to diminish the activity of some CPP
transfection agents.16 Although detailed siRNA protection and long-term stability analysis
remains to be performed, these data further suggest that p5RHH/siRNA nanoparticles might
provide therapeutic benefits when utilized for transfection in vivo.
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The use of siRNA as a therapeutic allows the treatment of disease through targeted
therapies based on a patient’s specific disease. By leveraging prior knowledge about the genomic
aberrations that contribute to disease pathologies, the efficacy of disease treatment can be
improved. For example, ATLL is driven by activation of both the canonical and non-canonical
NFκB pathways. As reviewed by Rauch and Ratner, the non-canonical pathway plays a larger
role in promoting anti-apoptotic protein expression than the canonical pathway, marking it as the
more highly desirable target for affecting the proliferation of ATLL cells.17 Our data utilizing
p5RHH-mediated siRNA delivery not only confirm this hypothesis but also reveal a synergistic
response when targeting both the canonical and non-canonical NFκB pathways with a single
p5RHH-based nanoparticle which simultaneously packages both p65 and p100/p52 siRNAs.
These results are important for the future treatment of ATLL given published results
questioning the efficacy of small molecule inhibitors of NFκB activation. In comparison with
currently available small molecule inhibitors of NFκB activation such as PS-341 (a proteasome
inhibitor) and Bay11-7082 (an IKK inhibitor), our approach provides direct inhibition of NFκB
through decreased NFκB subunit expression. The uncertainty surrounding the mechanism of
NFκB activation in ATLL cells suggests that direct downregulation of NFκB protein levels is the
most efficacious approach for inhibiting the anti-apoptotic mechanisms driven by NFκB
signaling.18
Initial studies in a spontaneous model of ATLL demonstrate that a single dose of siRNA
is enough to allow siRNA delivery into the tumor as imaged by ex vivo fluorescence imaging and
confirmed by confocal microscopy. Although siRNA appears to be limited to the tumor
periphery, ongoing work will include future experiments to determine if siRNA is able to enter
malignant cells, which appear to concentrate at the periphery of the tumor (Rausch, unpublished
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observations). Interestingly, IVIS imaging also demonstrates kidney localization of the particle
with minimal spleen or liver uptake. While the size of our nanoparticles would suggest minimal
kidney filtration into the urine, it appears that the kidneys are a primary source of clearance for
our nanoparticles. While further examination of p5RHH/siRNA nanoparticles is required in this
context, polyplexes and lipidic transfection agents have been shown to disassemble in the
glomerulus due to electrostatic competition for vector binding by the negatively charged
proteoglycans that make up the glomerular basement membrane. The liberated siRNA is then
filtered into the urine, where a portion is reabsorbed by the proximal tubule cells leading to
apparent kidney-specific localization.19
Despite this potential clearance mechanism, the use of p5RHH to mediate delivery
appears to increase the circulation half-life of the siRNA as compared to free siRNA. When
examining uptake of siRNA by proximal tubule cells in the kidney, naked siRNA was noted to
clear the kidney by 24 hours post-injection. In contrast, our findings show clear siRNA
localization to the kidney 24 hours after injection.20 In fact, future formulations with tuned
dissociation in the glomerulus may prove beneficial as long-circulating pegylated liposomes
have led to skin specific toxicities due to capillary deposition.21 By taking advantage of this
clearance mechanism, the pharmacokinetics of the siRNA delivery agent can be tuned to avoid
inappropriate biodistribution.
Prior attempts to target NFκB expression itself have focused on the use of naked
antisense DNA oligonucleotides or lentiviral shRNA expression, which has limited therapeutic
potential.22, 23 The use of antisense oligonucleotides is inefficient, requiring an order of
magnitude more therapeutic than our current siRNA formulation in vitro. On the other hand,
viral vectors for shRNA expression have encountered a variety of challenges in human trials
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ranging from induction of cancer to toxicity from saturation effects.24-26 We believe our initial
studies offer proof of concept that the use of p5RHH for highly efficient low toxicity transfection
of NFκB targeted siRNA may provide a therapeutically relevant strategy for the treatment of
ATLL and other hematologic malignancies, warranting further in vivo studies.
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Chapter 5
Conclusions and Future Directions
Successful application of siRNA as a therapeutic requires the development of vectors that
can promote cytoplasmic delivery of siRNA without inducing cytotoxicity. Towards this end,
short positively charged amphipathic peptides have demonstrated the ability to deliver siRNA
without inducing cell death.1 Unfortunately, these methods yield suboptimal transfection
efficiency due to endosomal entrapment. Nevertheless, due to their biodegradability and
construction from naturally occurring amino acids, peptide vectors represent a promising class of
siRNA vectors that is still in its infancy. The development of new peptide sequences holds
promise for improved siRNA release in the cellular milieu. Furthermore, understanding the
mechanism behind this release may provide a basis for further optimization of future peptides.
To avoid the endosomal entrapment that plagues existing peptide transfection agents, we
focused on peptides derived from melittin, the hemolytic component of honeybee venom.
Changes to melittin include modifications designed to decrease cytotoxicity, improve
electrostatic siRNA binding, and allow for pH triggered nanocomplex disassembly. Specifically,
this work takes advantage of N-terminal truncation of melittin, which our lab has previously
demonstrated to reduce melittin cytotoxicity by two orders of magnitude while retaining a
propensity for partitioning into lipid bilayers. In addition, amino acids found at high
concentration in DNA-compacting proteins such as protamine (arginine and histidine) are
appended to the C-terminus for improved siRNA binding and release in response to acidic pH.
In Chapter 2, melittin derivatives were screened for siRNA transfection. The physical
characteristics of the nanocomplexes they formed when combined with siRNA were
characterized, and their transfection efficiency was compared to standard lipid agents. After
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Figure 5.1 Mechanism of Cytoplasmic siRNA Delivery by p5RHH
p5RHH packages siRNA into nanoparticles 50 to 200 nm in diameter for cellular entry by
macropinocytosis. Endosomal acidification drives particle disassembly with release of p5RHH to mediate
endosomolysis. siRNA then accesses the cytoplasm to drive RISC assembly and mRNA degradation.

screening seven melittin derivatives, four were found to be capable of siRNA transfection. The
most active peptide, p5RHH is able to completely package siRNA at peptide to siRNA ratios
greater than 50 to 1 to form nanocomplexes. Zeta potential and dynamic light scattering reveal
that these complexes are stabilized by electrostatic repulsion with a particle size of 50 to 200 nm.
Unfortunately, the low magnitude of the surface charge (+12 mV) leads to an unstable
formulation with continued aggregation likely driven by hydrophobic interactions. This
aggregation results in a size distribution with multiple populations, as confirmed by deep-etch
electron microscopy. Continued aggregation leads to loss of transfection efficiency, pointing to
the importance of particle stabilization for sustained siRNA transfection. Formulations stable for
over 24 hours can be achieved by coating the nanoparticles with albumin. When compared to
Lipofectamine 2000, p5RHH is less efficient with an IC50 between 25 to 50 nM depending on
the cell type. Notably, p5RHH has limited vector-associated toxicity, as transfection with
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scrambled siRNA does not alter cell viability at all tested doses. These findings indicate that the
melittin derivative, p5RHH, is a safe and effective siRNA transfection agent with potential utility
as a basic science research tool and as a clinically relevant therapeutic.
Based on our examination of p5RHH’s mechanism of action in Chapter 3, p5RHH enters
the cell by macropinocytosis as a component of p5RHH/siRNA nanoparticles, and is released
upon exposure to acidic pH for endosomolysis by directly disrupting the endosomal membrane
(Figure 5.1). Release of p5RHH occurs concurrently with siRNA release, a property that is
critical for successful induction of RNAi. Comparison with non-functioning melittin derivative,
p5RWR, demonstrates that an inability to release siRNA from the vector prevents GFP
knockdown, even when endosomal escape is induced by incubation with endosomolytic agents
which allows Cy3-labeled oligonucleotides to distribute throughout the cytoplasm. To assess the
ability of p5RHH to mediate endosomal escape, chloroquine application, which was intended to
potentiate endosomal escape, provided no additional benefit, revealing that p5RHH/siRNA
nanoparticles are not trapped to any extent in the endosomes. To our knowledge, even the most
efficient previously published peptide vectors have shown improvement upon treatment with
chloroquine, implying some degree of endosomal entrapment.2
We note that p5RHH does not provide exceptional transfection efficiency in vitro as
compared with previously published peptide transfection agents. The most likely sources of
inefficiency are incomplete siRNA release from the peptide vector and particle instability. Our
data indicate that endosomolysis may occur before complete siRNA release, possibly limiting
siRNA access to the RISC. A quantitative comparison of RISC-associated siRNA to total siRNA
delivered is required to address this potential source of inefficiency. Furthermore, a more
detailed characterization of the type of endocytic vesicles encountered during intracellular
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processing and delineation of the exact point of endosomal escape may allow fine-tuning of
particle disassembly to match the environmental triggers available along the endosome/lysosome
pathway.3, 4 Additionally, it is likely that not all siRNA included in the formulation is delivered
to cells. It is possible that some of the larger aggregates may sequester siRNA in an inactive
fraction. These findings suggest that further analysis of the current formulation is required,
including analysis of transfection efficiency as a function of nanoparticle size. Alternatively, new
synthetic methods that entail two-phase formulation, such as solvent evaporation, potentially
have utility in controlling particle size and promoting a more homogenous population of particles
with uniform transfection capacity.5, 6
Despite a heterogeneous particle size distribution, p5RHH/siRNA nanocomplexes exhibit
considerable potential for the treatment of diseases characterized by endothelial dysfunction or
diseases confined to the vascular compartment. As illustrated in Chapter 4, examples include
solid tumors, angiogenesis, advanced atherosclerosis, and leukemia. Initial studies addressing the
treatment of these diseases include knockdown of STAT3 in B16-F10 mouse melanoma cells,
STAT3 in primary human umbilical vein endothelial cells, JNK2 in RAW264.7 mouse
macrophages, and NFκB in F8 leukemia/lymphoma cells. Transfection efficiency varies by cell
type with an IC50 as low as 25 nM in macrophages, a finding that may be attributable to the
preference for p5RHH/siRNA nanoparticles to enter cells via fluid-phase uptake. Nevertheless,
these data reveal a broad applicability for p5RHH in the transfection of many relevant cell types
without significant cytotoxicity. The promising nature of p5RHH-mediated transfection and the
observation of albumin stabilization of nanoparticle size suggest that direct injection of
p5RHH/siRNA nanoparticles into the bloodstream can result in meaningful delivery of
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p5RHH/siRNA nanoparticles to disease sites in vivo with particle stabilization induced by
coating with native serum albumin.
Initial studies examining delivery of p5RHH/siRNA nanoparticles to spontaneous tumors
in a murine model of ATLL indicate delivery to the tumor periphery with uptake in the kidneys
but no deposition in traditional clearance organs such as the liver or the spleen. Kidney
accumulation may be an indication of an unknown mechanism of targeting to the proximal
tubules of the kidney or possible p5RHH/siRNA nanocomplex disassembly on the glomerular
basement membrane. A more careful analysis of p5RHH/siRNA biodistribution and
pharmacokinetics is required to determine what percent of the injected dose is able to reach the
tumor. In addition, achieving significant nanoparticle delivery to tumors in vivo may require
additional strategies to modify vascular permeability or improve transcytosis to bypass vascular
constraint by endothelial tight junctions.
Melittin derivatives exhibit efficient siRNA transfection attributable to lysis of
endosomal membranes without inducing cytotoxicity in vitro. In view of promising in vivo
proof-of-concept studies, p5RHH/siRNA nanoparticles may exhibit utility in the treatment of
many diseases. Ultimately, improved peptide-mediated transfection may require new peptides
with enhanced siRNA-release characteristics or development of new formulation methods to
increase particle homogeneity. Nevertheless, the data presented in this thesis demonstrate that
melittin derivatives alone facilitate delivery of siRNA to the cytoplasm and suggest general
guidelines that may serve to direct the development of new peptide vectors for improving the
efficiency of siRNA therapeutics.
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Appendix I
Stimulation of Transvascular Transport for
Improvement of Nanoparticle Biodistribution
AI.1 Abstract
The intact endothelial barrier prevents extravasation of particles larger than 2 nm,
effectively resulting in vascular constraint of nanoparticles. Fortunately, natural mechanisms
such as caveolar transcytosis exist to improve transport of macromolecules including lipoprotein
particles and albumin into the extravascular space. Existing work indicates that endothelial cells
are specially adapted for transcytosis via increased expression of caveolar vesicles.
Consequently, stimulating caveolar uptake may be an appropriate method of also increasing
nanoparticle transcytosis by endothelial cells. To this end, we have tested lipid-conjugated
peptides known to activate the signaling pathway controlling caveolar endocytosis as a method
of increasing rates of transcytosis. The peptide myr-SIRK indirectly stimulates caveolin-1
phosphorylation, an early step in caveolar uptake, but does not induce tight junction disassembly.
When utilized for the stimulation of human umbilical vein endothelial cell (HUVEC)
monolayers, myr-SIRK increases the transcytosis of albumin, a native cargo for caveolar
transcytosis. Importantly, myr-SIRK also increases the fluid phase transport of 70 kDa dextran, a
5 nm macromolecule, which has low native endothelial permeability, but not inulin, a small
molecule whose transport is determined by paracellular diffusion. To determine the utility of this
strategy in transcytosis of therapeutics, we also demonstrated that myr-SIRK can stimulate the
transport of antibodies. We envision the future incorporation of this lipid-peptide construct into
perfluorocarbon nanoparticles to enable tissue-targeted delivery of myr-SIRK for localized
activation of endothelial transcytosis.
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AI.2 Introduction
Nanoparticles are hypothesized to dramatically augment the efficacy of drug delivery by
aiding the delivery of drugs to specific sites with minimal “off-target” delivery. Nonetheless,
nanoparticles have not provided the revolutionary benefits that were expected. Based on data
analyzing nanoparticle biodistribution, it is clear that vascular constraint of nanoparticles limits
the ability to utilize nanoparticles as delivery vehicles to extravascular targets.1, 2 For example,
computational work modeling IgG antibody (180 kDa) penetration of tumors suggests that use of
these natural nano-structures is limited by vascular extravasation.3 When considering the
parameters that determine antibody concentration in the tumor, the authors conclude that
diffusion away from the vasculature is often much quicker than extravasation with antibody
consistently remaining at a low concentration in the tumor. Even for antibodies with a maximal
dimension of 15 to 20 nm, endothelial tight junctions with a spacing of 2 nm are a significant
barrier blocking access to the extravascular space.4
Consequently, the challenge of enabling widespread use of nanoparticle therapeutics in
the clinical setting requires improved nanoparticle biodistribution to extravascular targets.
Current techniques for improving nanoparticle delivery past the endothelial barrier rely on
improving paracellular transport or actively targeting nanoparticles to caveolar markers in order
to promote transcytosis.5 For example, an NIH symposium exploring the challenges of Enhanced
Permeability and Retention (EPR) of nanoparticles in tumors suggests that increased
nanoparticle delivery can be achieved via transient induction of hypertension to improve
convective transport through discontinuous angiogenic vessels or decreased tight junction
integrity through the use of bradykinin.6 These strategies have previously been shown to
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augment therapeutic nanoparticle delivery but will also alter the vasculature on a systemic level,
potentially causing harm to patients.7
Using an alternative strategy, Schnitzer et al. have improved targeted delivery of
nanoparticles into the extravascular space by conjugating antibodies targeted against caveolar
markers to nanoparticle surfaces.8, 9 These antibodies increase association of nanoparticles with
endothelial caveolae to promote direct nanoparticle transcytosis.10, 11 Additionally, by choosing
tissue-specific caveolar markers, nanoparticles can be targeted for transcytosis across the
vascular bed of specific organs, such as the lung.12 Unfortunately, the rate of transcytosis appears
to vary depending on the tissue with tumor transcytosis (minutes-hours, unpublished data)
occurring an order of magnitude slower than lung transcytosis (seconds).9
In additional work, Ruoslahti et al. have focused on the development of “tumor
penetrating peptides” based on the C-end Rule in which arginines at the C-terminal end of a
peptide in the context of R/KxxR/K-OH are able to bind to neuropilin-1 on endothelial cells to
promote increased extravasation of covalently attached nanoparticles or even free
nanoparticles.13, 14 Although the authors opine that the mechanism responsible for increased
nanoparticle extravasation is based on stimulation of active transcytosis, a more likely
mechanism is an increase in paracellular transcytosis due to tight junction disassembly.
Specifically, previous work has shown that antibodies that cause neuropilin-1 oligomerization
can lead to vascular leakiness due to tight junction disassembly.15-17 From this standpoint, tumor
penetrating peptides may actually be of limited utility for continued dosing, as prolonged
vascular leakiness can cause intratumoral hypertension, decreasing vascular patency and slowing
convection in the extravascular space.6, 18, 19
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Based on these previously published strategies, it appears that tissue-specific activation of
transcytosis may be an unexplored means of augmenting nanoparticle delivery into a tissue of
interest via fluid phase transport. Such a strategy would be analogous to tumor specific induction
of paracellular transport by tumor-penetrating peptides without the concomitant increase in
vascular leakiness. Moreover, these strategies can also augment the delivery of nanoparticles
targeted to caveolar markers. To achieve this goal, lipid-conjugated peptides known to increase
the rate of caveolar endocytosis are leveraged to stimulate direct transcytosis in HUVEC
monolayers.20
The cellular signaling involved in caveolar endocytosis is complex; however, detailed
characterization of albumin transcytosis indicates that albumin binding to its cell surface receptor
activates caveolin-1 and dynamin phosphorylation downstream of inhibitory G-protein coupled
receptor activation.20, 21 Notably, Gi signaling can be directly stimulated by introduction of
peptides with the sequence SIRKALNILGYPDYD into the cytoplasm of a cell.22, 23 Use of cell
permeable myristoylated-SIRK leads to increased albumin uptake in cultured cells, but the
ability of these myristoylated peptides to directly stimulate transcytosis in endothelial
monolayers has not been established.20 Our work indicates that myr-SIRK not only increases
transcytosis of native caveolar cargo but also increases fluid phase transport of cargos such as
dextran and antibodies, which suggests the ability to increase nanoparticle transport as well.
These peptides have the potential to be incorporated into perfluorocarbon (PFC) nanoparticles
that can serve as a platform to directly deliver transcytosis stimulating lipid-peptide constructs to
inflamed or angiogenic vasculature by utilizing targeting ligands for VCAM-1 or α β3.
υ

AI.3 Materials and Methods
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AI.3.1 Synthesis of myr-SIRK
SIRK was synthesized using FMOC chemistry on a CS Bio C5136 (Menlo Park, CA) and
conjugated to myristic acid (Sigma, St. Louis, MO). myr-SIRK was purified by reversed-phase
HPLC and dried by lyophilization.
AI.3.2 HUVEC Culture and Monolayer Preparation
Human umbilical vein endothelial cells (HUVECs) were purchased from Lifeline
Technologies (Frederick, MD) and cultured in VascuLife Basal Medium (Lifeline Technologies)
supplemented with 5 ng/mL EGF, 5 ng/mL bFGF, 15 ng/mL IGF-1, 50 µg/mL ascorbic acid, 1
µg/mL hydrocortisone hemisuccinate, 0.75 U/mL heparin sulfate, 10 mM L-glutamine, and 2%
fetal bovine serum in accordance with manufacturer instructions. For all experiments, HUVECs
were used at passage three. For preparation of monolayers (Figure AI.1), 24-well transwell
inserts (0.8 µm pore size PET membranes, BD Falcon, Franklin Lakes, NJ) were coated with 300
µL 1% gelatin (2% porcine gelatin stock (Sigma, St. Louis, MO) diluted 1 to 2 with sterile H2O)
for 30 minutes, followed by cell seeding at a density of 50,000 cells/well in 350 µL HUVEC
media supplemented with antibiotics. The bottom chamber received 1.5 mL of HUVEC media
supplemented with antibiotics. Media was changed every other day by removing the media in the
cup, then the media in the well with the media in the well replaced first.

Figure AI.1 HUVEC Monolayer Culture
HUVECS are cultured in a monolayer on gelatin-coated PET membranes with a pore size of 0.8 µm.
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AI.3.3 Monolayer Resistance Measurements
Monolayer measurements were performed using an Endohm-6 electrode (World
Precision Instruments, Sarasota, FL). Briefly, the electrode and cup were sterilized with ethanol
and allowed to dry. 1.5 mL HUVEC media with antibiotics was transferred to the electrode cup.
Transwell inserts were transferred to the cup and resistance was measured, taking care to avoid
air bubbles between the transwell insert and the bottom of the cup. Measurements were taken
every other day to follow monolayer formation. Monolayers were considered complete when
resistance reached ~44 Ω.
AI.3.4 Caveolin-1 Western Blotting
HUVECs were cultured in 6-well plates at 200,000 cells/well for 24 hours in HUVEC
basal media without supplements or FBS. HUVECs were then stimulated with 1 to 10 µM myrSIRK, DMSO control, or full HUVEC media as a positive control. Cells were then washed with
ice-cold PBS without Ca+2/Mg+2 and lysed with RIPA buffer at the indicated time points. Cell
lysates were collected and stored at -80°C before resolution by polyacrylamide gel
electrophoresis on a 10% Bis-Tris gel (Lifeline Technologies, Frederick, MD). After transfer to
0.22 µm nitrocellulose, membranes were first probed for phospho-Caveolin-1 using rabbit antipCav-1 polyclonal antibody (1:1,000, Cell Signaling) and subsequently stripped and re-probed
for Caveolin-1 (rabbit polyclonal, 1 to 1,000, Cell Signaling). GAPDH was probed as a loading
control.
AI.3.5 Transcytosis Stimulation
HUVECS were cultured on transwell inserts as described above. After monolayers were
confluent (~1 week), media in the apical chamber was replaced with full HUVEC media
supplemented with antibiotics containing either FITC-inulin (15 nM, Sigma), FITC-albumin (1.5
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nM, Sigma), 70 kDa FITC-dextran (3 nM, Sigma) or Cy3 Goat-anti-Mouse IgG (75 µg/mL,
Jackson Immuno Research, West Grove, PA). Cells were stimulated with either DMSO or 1 to
100 µM myr-SIRK. Transport controls included 1-hour pretreatment of cells with 0.1% Triton-X
to remove all cells or 10 mM EGTA to remove tight junctions. Transwell resistance was
measured to ensure complete removal of cells by Triton-X treatment. 100 µL of media from the
bottom well was removed at the indicated time points and the fluorescence was measured in a
96-well plate. Each experiment included three replicates. Data are presented as an average from
three separate experiments.
AI.3.6 Direct Transcytosis
HUVECs were seeded on transwell membranes with media changed every other day for 1
week. Cells were then incubated in 1.5 nM FITC-albumin at 4°C for 30 minutes. After the
incubation, cells were washed with ice-cold PBS three times and reintroduced to the tissue
culture incubator. FITC-Albumin transcytosis at 40 minutes and 2 hours was recorded by
removing 100 µL for fluorescence measurements.

AI.4 Results
AI.4.1 Stimulation of Caveolin-1 Phosphorylation
According to studies investigating albumin transport, activation of caveolin-1 is required
for the caveolar endocytosis. To determine if myr-SIRK could directly stimulate this process,
HUVECs were stimulated with 1, 2.5, and 10 µM myr-SIRK. Western blotting demonstrates that
Caveolin-1 phosphorylation begins as soon as 15 minutes and continues for up to 1 hour at 10
µM myr-SIRK (Figure AI.2). Notably, caveolin-1 phosphorylation is higher when stimulating
with myr-SIRK than with HUVEC media containing growth factors and 10% FBS.
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Figure AI.2 myr-SIRK Stimulates Caveolin-1 Phosphorylation
Western blotting confirms stimulation of Caveolin-1 phosphorylation by 15 minutes, lasting for up to 60
minutes.

AI.4.2 No Adverse Effects on HUVEC Monolayer Integrity
To determine if myr-SIRK negatively impacts tight junction integrity, the transwell
resistance of myr-SIRK stimulated HUVEC monolayers was measured (Figure AI.3a). Triton-X
treatment decreased resistance to 22 Ω, the same as unused new transwell inserts. Gelatin coating
did not increase resistance (unpublished observations). Treatment with EGTA indicates that a
transwell resistance of 32 Ω is attributable to cells alone with a further 10 Ω attributable to tight
junction formation, in accordance with previously published values.24 These data also reveal that
DMSO and 10 µM myr-SIRK do not affect tight junction formation, suggesting that any increase
in transwell transport is attributable to active transcytosis by the cells and not due to increased
paracellular diffusion.

110

Figure AI.3 myr-SIRK Stimulation Increases Caveolar Transcytosis
(a) Transwell resistance measured 2 hours after myr-SIRK stimulation reveals tight junction integrity
remains intact. (b) myr-SIRK stimulates transcytosis of prebound albumin. (c-e) myr-SIRK stimulates an
increase in albumin and dextran transport but not inulin.

AI.4.3 Increased Transcytosis of Caveolae-Targeted and Non-Targeted Cargo
Transport experiments indicate that myr-SIRK stimulation can increase the transport of
receptor-bound native caveolar cargo (albumin) as well as nonspecific fluid phase transport of 70
kDa dextran (diameter ~5 nm) (Figure AI.3c,d). This increase in transport is seen as early as 20
minutes after stimulation and continues for 24 hours. As a control, FITC-inulin with a molecular
weight of 2 to 5 kDa primarily passes through monolayers by paracellular diffusion, and its
transport is not altered by myr-SIRK, providing further evidence that myr-SIRK does not affect
paracellular diffusion (Figure AI.3e). Although there is minimal evidence for a change in tight
junction integrity and consequently paracellular transport, the analysis of active transcytosis can
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Figure AI.4 myr-SIRK Stimulates Antibody Transcytosis
myr-SIRK stimulates dextran (a), albumin (b), and antibody transport (d), but not inulin (c) transport.
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be isolated by observing the transport of pre-bound albumin. In these assays, it is clear that myrSIRK can increase the rate of albumin transcytosis by HUVEC cells (Figure AI.3b).
AI.4.4 Stimulation of Antibody Transcytosis
Antibody transcytosis in the presence of myr-SIRK was quantified to determine if
increased caveolar-based transcytosis could improve the transport of therapeutic agents. These
data show that antibody transport is increased, along with both 70 kDa dextran and albumin
(Figure AI.4a,b). Unfortunately, these data also reveal that HUVEC transcytosis is variable,
depending on the batch of HUVECs used for the assays. Although the resistance measurements
were the same between batches, baseline transport of inulin, albumin, and dextran are all
increased by an order of magnitude with a new batch of HUVECs purchased from Lifeline
Technologies (Figure AI.4). Unfortunately, it is unclear whether increased inulin transport in this
second batch is due to increased paracellular diffusion or increased transcytosis at baseline.
Despite the increased baseline transport, myr-SIRK stimulation is still able to induce an increase
in antibody transport (Figure AI.4d), providing further support that stimulated caveolar transport
can improve delivery of therapeutic macromolecules or nanoparticles to extravascular sites.

AI.5 Discussion
Transvascular transport is controlled by the endothelium and can be separated into
transcellular or paracellular transport. Paracellular transport relies on diffusion past endothelial
tight junctions and is limited to particles smaller than 2 nm. Transcellular transport is often
attributed to caveolar transcytosis and can transport particles of up to 100 nm.5 Schnitzer et al.
have demonstrated the importance of caveolar transcytosis by endothelial cells in the
transvascular delivery of albumin and albumin-bound molecules.10, 11 This constitutive process
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can be leveraged for the transport of nanoparticles by targeting nanoparticles to endothelial
caveolae via surface modification with antibodies to caveolar surface markers. For instance,
conjugation of aminopeptidase P (a marker of caveolae on the endothelium of lung tissue)
antibodies to the surface of nanoparticles allows nanoparticles to be quickly transcytosed and
delivered into the extravascular space in the lungs.8 Unfortunately, it appears as though the speed
of this process is dependent on the tissue, as lung transcytosis occurs an order of magnitude
quicker than transcytosis in the tumor. Moreover, this transport paradigm requires the
challenging process of identifying endothelial surface markers which are localized to caveolar
structures.25
As an alternative, stimulation of caveolar transcytosis in an organ-specific manner may
serve as an additional route to improve transvascular transport. By increasing the rate of
transcellular transport, nanoparticles can be actively taken up by both active targeting as well as
fluid phase transport and delivered to the interstitial space. Similar methods have been published
by Ruoslahti et al. by increasing paracellular transport in tumors.26 To this end, our data suggest
that, in in vitro tissue culture assays, stimulation of caveolar transcytosis by myr-SIRK can
improve the transport of both caveolar targeted (albumin) and non-targeted (dextran) transport
without altering endothelial integrity. Importantly, transport of natural “nanoparticles” such as
IgG antibodies with a maximum dimension of ~15 to 20 nm can be increased as well.
Unfortunately, our data also highlight the difficulties of working with primary endothelial
cells, including heterogeneity in basal transport rates and irregularities in cell behavior in a nonnative setting. Moreover, HUVEC monolayers do not recapitulate vascular endothelium due to a
lack of shear stress in the lumen and supporting pericytes on the basal surface. Under these in
vitro conditions, HUVECs are known to produce leaky monolayers, which may contribute to a
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high baseline transport of control molecules in the un-stimulated condition.27-29 Additionally,
shear stress is known to transiently induce caveolin-1 phosphorylation in cultured HUVECS,
suggesting that media exchange can activate HUVEC monolayers, further increasing the baseline
transport measured at the early 20-minute time point.30
Based on these findings, our observation of increased transport in myr-SIRK-treated
monolayers suggests that despite the high basal transport in vitro, myr-SIRK stimulation is able
to yield a quantifiable increase in transport. Therefore, it is likely that the effects of myr-SIRK
will be greater in vivo where paracellular transport is lower and basal transcytotic rates are not
transiently augmented by media exchange. Moreover, cultured HUVECs are known to harbor
fewer caveolae than native endothelium. An increased number of caveolae in vivo may indicate
that maximum transport by native endothelium will be higher than that of HUVEC monolayers.31
Taken together, we expect stimulation of transcytosis to provide additional benefits in
nanoparticle extravasation in vivo over baseline passive diffusion or caveolae targeted transport.
Before these studies can be accomplished, targeting mechanisms to deliver myr-SIRK in
vivo must be developed. In unpublished work from our lab, Sinha et al. demonstrate that lipidconjugated peptides can be delivered into the cytoplasm of cells to alter PAR-1 signaling using
perfluorocarbon (PFC) nanoemulsions. This finding implies that PFC nanoparticles are a viable
platform for the targeted delivery of myr-SIRK to endothelium based on their cell surface
markers.32 Combined with PFC delivery strategies, the use of dorsal skin windows or intra-vital
2-photon microscopy can allow the quantitative measurement of myr-SIRK stimulated
transcytosis in vivo.9
The need for new mechanisms to drive extravasation of nanoparticles is greatest in
tissues with low paracellular transport and slower rates of transcytosis, notably tumors and
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cardiac tissue. By stimulating transcytosis in an organ-specific manner, nanoparticle
biodistribution can be improved without the induction of vascular leakiness. Such strategies can
be used to increase the transport of caveolae-targeted cargos as well as the fluid phase transport
of non-targeted cargos. Although a robust delivery mechanism for myr-SIRK remains to be
tested, stimulated transcytosis remains a potential mechanism by which nanoparticle therapy can
be improved.
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